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 Matrix metalloproteinase-13 (MMP-13) has long been considered as a target 
for the inhibition of the progression of osteoarthritis (OA), rheumatoid arthritis (RA) 
and breast cancer. Preclinical data implicate human matrix metalloproteinase13 
(MMP-13) as the direct cause of irreversible cartilage damage in arthritic conditions. 
MMP-13 catalyzes the cleavage of type II collagen (the main structural component of 
the articular cartilage) and also recently found in breast cancer, but not in normal 
adults. Therefore, this protease is an important target for the inhibition of progression 
of OA, RA and breast cancer. Our recent results suggest that selective inhibition of 
MMP-13 may be achieved by targeting its hemopexin (Hpx) domain, which is critical 
for substrate specificity. We applied in silico structure-based high-throughput virtual 
screening (HTVS) and identified 7 ligands from the Maybridge, PubChem and 
Binding libraries which uniquely interact with the putative functional residues of the 
MMP-13 Hpx domain.  
 We experimentally validated these potential and selective MMP-13 inhibitors 
in vivo and their backbone structural scaffold could serve as building blocks in 
designing drug-like molecules for OA, RA, breast cancer and other inflammatory 
disorders. Systematic structure based virtual screening and X-ray crystallography (to 
solve three dimensional (3D) structure of the Hpx domain, in complex with these lead 
molecules), have been used for rational search for better potent drug like molecules 
(however we solved the apo Hpx domain and presented in detail in following 
sections). At the same time, the complex 3D-structures give adequate insight on the 
interaction between the drug molecules and the enzyme and more potential ways for 




CHAPTER 1. INTRODUCTION 
 
1.1 MATRIX METALLOPROTEINASES (MMPs) 
 Matrix metalloproteinase’s (MMPs) are a family of zinc-dependent 
endopeptidases (Baragi et al., 2009). As a family, MMPs can cleave virtually any 
component of the extracellular matrix (ECM) (Egeblad and Werb, 2002). 
Collectively, they are capable of degrading all kinds ECM proteins. They were first 
described in vertebrates in 1962 (Gross and Lapiere, 1962), including humans, but 
have since been found in invertebrates and plants also. Since then, the MMP family 
has been extensively studied in a multitude of animal and tissue models (Birkedal-
Hansen, 1988).  
 
1.2 BIOLOGICAL ROLE OF MMPs 
 MMPs play a central role in morphogenesis, wound healing, tissue repair and 
remodelling in response to injury, e.g. after myocardial infarction, and in progression 
of diseases such as atheroma, arthritis, chronic tissue ulcers and cancer (Fig. 1). 
Expression of MMPs is low in normal cells, and these low levels allow for healthy 
connective tissue remodelling. In pathologic conditions, the signal peptide is cleaved 
for the enzyme to become active. Later the level of MMP expression increases 
considerably, resulting in aberrant connective tissue destruction. Excess MMP 
production is also associated with the pathology of several diseases, including 
periodontitis, atherosclerosis, tumour invasion/metastasis and arthritis (Borden and 
Heller, 1997; Brinckerhoff et al., 2000; Vincenti, 2001).  
 MMPs are also known to be involved in the cleavage of cell surface receptors 
and chemokine/cytokine in/activation (Van Lint and Libert, 2007). They are also 
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thought to play a major role in cell behaviours such as cell proliferation, migration 
(adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defence. 
 
 
Figure 1. Biological role MMPs in cancer. Diverse regulatory signals initiate a 
cascade of events that lead to the generation of functional MMPs, which are 
membrane type (MT-MMPs) or proMMP. Active MMPs are involved in a 
number of processes that promote cancer development, including promoting 
genetic instability, cell growth, angiogenesis and invasion. They also interfere 
with apoptosis induction and host antitumor immune response. 
 
1.3 SIGNIFICANCE OF MMPs IN ARTHRITIS AND CANCER 
 Many types of arthritis and cancer are inflammatory disorders. Arthritis 
literally means an inflammation (itis) of joints (arthr). In several types of arthritis, the 
body’s inflammatory response is misdirected. The pain, redness, heat, swelling and 
other harmful effects of inflammation can be treated with medication, diet and 
exercise.  
 Excess matrix degradation is one of the hallmarks of cancer and is an 











MMP roles in CANCER
Genetic instability Cell growth Angiogenesis Invasion Apoptosis Immune response
3 
 
When a tumor cell acquires the ability to invade and destroy normal tissue, it is 
termed malignant. The ability to form tumors at a distant site (metastasis) is a 
characteristic of highly malignant cancers with poor clinical outcome. For invasion 
and metastasis to occur, the tumor cell must bypass the basement membrane. The 
basement membrane is a specialized structure containing ECM components that 
provides a stable foundation on which normal epithelial cells adhere (Schwarzbauer, 
1999). During invasion, the tumor cell penetrates the basement membrane underlying 
the tumor. It then moves through ECM to reach the blood circulation either through 
lymphatic vessels or through the blood vasculature. Therapies designed to stop the 
ECM that is critical for many of these steps represent a rational approach to 
controlling cancer (Stetler-Stevenson et al., 1996). 
 Most cells in the body express MMPs, even though some enzymes are often 
associated with a particular cell type. For example, the principle substrate of MMP-2 
(also known as gelatinase A) and MMP-9 (also known as gelatinase B) is type IV 
collagen in the basement membrane and thus, these enzymes are usually expressed by 
endothelial cells, although other cells (e.g. stromal fibroblasts, macrophages, tumor 
cells) also express them (Borden and Heller, 1997; Vincenti, 2001). MMP-3 (also 
known as stromelysin) activates MMP-1 (also known as collagenase-1) and cleaves a 
broad range of matrix proteins (Vincenti et al., 1996); MMP-1, which is an interstitial 
collagenase, and MMP-3 are among the most ubiquitously expressed MMPs. In 
contrast, MMP-13 (also known as collagenase-3) has a more restricted pattern of 
expression within connective tissue, and is usually produced only by cartilage and 
bone during development, and by chondrocytes in osteoarthritis (OA) and rheumatoid 






Figure 2. Proposed model for cellular degradation of the extracellular matrix 
(ECM) in response to tensile and compressive forces generated during tumor 
growth. Fundamental mechanics principles show that tumor growth and 
expansion would cause increasing tension and compression in the surrounding 
stroma. This suggests that the tension in the collagen within the stroma likely 
assists in trapping and containment at early stages of cancer cell proliferation by 
preventing matrix degradation. MMPs secreted by adipocytes within the stroma 
are unable to cleave the collagen. In response to the increased forces within the 
ECM, epithelial myofibroblasts then attach to the ECM to reorient the collagen, 
sense the increased tension (stiffness) in the collagen and increase their tensile 
traction force on the collagen, which results in unwinding of the triple helix, 
allowing MMP entrance and cleavage of the α-chains. Figure obtained from 
(Torzilli et al., 2012). 
 
 Expression of MMPs is low in normal cells, and these low levels allow for 
healthy connective tissue remodeling. In pathologic conditions, however, the level of 
MMP expression increases considerably, resulting in aberrant connective tissue 
destruction. Excess MMP production is associated with the pathology of many 
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diseases, including periodontitis, atherosclerosis, tumor invasion/metastasis and 
arthritic disease (Brinckerhoff et al., 2000; Nagase and Woessner, 1999; Vincenti, 
2001). In rheumatoid arthritis (RA) and OA, connective tissue destruction is mediated 
primarily by chondrocytes, by synovial fibroblasts and on occasion, by osteoclasts 
(Goldring, 2000; Han et al., 2001; Mengshol et al., 2000; Vincenti and Brinckerhoff, 
2001). 
 The interstitial collagens (types I, II and III), are the principle targets of 
destruction, and the secreted collagenases (MMP-1 and MMP-13) have the major role 
in this process. These MMPs are induced in response to the cytokines and growth 
factors that are usually found in arthritic joints. MMP-9 is also inducible, but its role 
in connective tissue destruction in arthritis appears to be secondary, since it 
contributes to the degradation of collagen only after the chains of the triple helix have 
been cleaved by interstitial collagenases (Nagase and Woessner, 1999). In contrast, 
MMP-2 and MMP-14 (membrane type 1 MMP), are constitutively expressed, with 
minimal regulation, and they may have a relatively minor role in the pathophysiology 
of arthritis. Thus, the collagenases MMP-1, MMP-8 and MMP-13 have the unique 
ability to cleave the triple helix of collagen, thereby allowing the chains to unwind; 
the chains then become susceptible to further degradation by other MMPs. Recently, 
MMP-8 (traditionally termed neutrophil collagenase) has been found in arthritic 
lesions, even in the absence of neutrophils, indicating that chondrocytes, and perhaps 
synovial cells, can produce this enzyme (Shlopov et al., 1997; Tetlow et al., 2001). 
MMP-13 may have a particular role in cartilage degradation because it is expressed 
by chondrocytes, and because it hydrolyzes type-II collagen more efficiently than the 
other collagenases (Mitchell et al., 1996). However, MMP-1 is more abundant and it 
also degrades interstitial collagens effectively (Nagase and Woessner, 1999; Vincenti, 
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2001). We will, therefore, focus this discussion on the mechanisms controlling 
transcription of MMP-1 and MMP-13 in arthritic disease, although the concepts may 
be applicable to other members of this gene family and to other pathological 
conditions. 
 
1.4 MMPs A TARGET FOR DRUG DEVELOPMENT 
The important role of MMPs in tumor progression and inflammation has 
prompted the development of several MMP inhibitors as cancer and arthritis 
therapeutics (Coussens et al., 2002; Egeblad and Werb, 2002; Overall and Lopez-
Otin, 2002). To date, clinical trials of these inhibitors have proven quite 
disappointing, possibly also because of the relatively poor comprehension of the 
details of MMP regulation, cellular function and interactions at the time the trials 
were designed (Coussens et al., 2002; Leeman et al., 2002; Overall and Lopez-Otin, 
2002). The most common cancer prevalence among the women population is the 
breast cancer. It has been reported that MMP-13 is a highly expressed secretion 
protein in breast cancer tissue. It has the potential to be a new tumor marker for breast 
cancer diagnosis (Chang et al., 2009). 
 Recent data have expanded the concept that inflammation is a critical 
component of tumour progression (Coussens and Werb, 2002). Degradation of 
extracellular matrix is crucial for malignant tumour growth, invasion, metastasis and 
angiogenesis. Elevated levels of distinct MMPs can be detected in tumour tissue or 
serum of patients with advanced cancer and their role as prognostic indicators in 
cancer has been studied. In addition, therapeutic intervention of tumour growth and 
invasion based on inhibition of MMP activity is under intensive investigation and 
several MMP inhibitors are in clinical trials for cancer treatment (Vihinen and Kahari, 
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2002). On the other hand, MMPs are also being considered to be prognostic markers 
of OA and RA which are autoimmune diseases, characterized by chronic 
inflammation of joints which gradually erodes cartilage and bone and also cancer.  
 
1.5 REGULATION OF MMPS BY TISSUE INHIBITORS OF 
 METALLOPROTEINASE’s  
MMPs are multi-domain proteins and their activities can be regulated by tissue 
inhibitors of metalloproteinase’s (TIMPs) (Nagase et al., 2006). The TIMP family at 
present comprises four members (TIMP-1 to TIMP-4) of relative molecular mass 
ranging from 22 to 30 kDa, with 40–50% sequence identity. All TIMPs inhibit active 
MMPs with relatively low selectivity, forming tight non-covalent 1:1 complexes 
(Willenbrock and Murphy, 1994). MMPs are regulated by activation of the precursor 
zymogens and inhibition by endogenous TIMPs. Thus, the balance between MMPs 
and TIMPs is critical for eventual ECM remodelling in tissues (Nagase et al., 2006). 





Table 1. Biological activities mediated by MMP cleavage 
 
Biological effect Responsible MMP(s) Substrate cleaved 
Keratinocyte migration and re-epithelialization MMP-1 Type I collagen 
Osteoclast activation MMP-13 Type II collagen 
Neurite outgrowth MMP-2 Chondroitinsulphate proteoglycan 
Adipocyte differentiation MMP-7 Fibronectin 
cell migration MMP-1,-2, and -3 Fibronectin 
cell migration MT1-MMP CD44 
Mammary epithelial cell apoptosis MMP-3 Basement membrane 
Mammary epithelial alveolar formation MMP-3 Basement membrane 
Epithelial-mesenchymal conversion (mammary epithelial 
cells) 
MMP-3 E-cadherin 
Mesenchymal cell differentiation with inflammatory 
phenotype 
MMP-2 Not identified 
Platelet aggregation MMP-1 Not identified 







Generation of endostatin-like fragment MMPs Type XVIII collagen 
Increased bioavailability of IGF1 and cell proliferation 
MMP-1, -2, -3, -7 (Miyamoto et al., 
2004) 






Activation of VEGF MMPs CTGF 
Epithelial cell migration 
MMP-2, MT1-MMP and  
MMP-19 (Sadowski et al., 2003) 
Laminin 5g2 chain 
 




Apoptosis (amnion epithelial cells) Collagenase Type I collagen 
Pro-inflammatory MMP-1, -3, and -9 
Processing IL-1h from the 
precursor 
Tumor cell resistance MMP-9 ICAM-1 
Anti-inflammatory MMP-1, -2, and -9 IL-1h degradation 
Anti-inflammatory MMP-1, -2, -3, -13, -14 
Monocyte chemoatractant protein-
3 
Increased bioavailability of TGF-h MMP-2,-3,-7 decorin 
Disrupted cell aggregation and increased cell invasion MMP-3, MMP-7 E-cadherin 
Reduced cell adhesion and spreading MT1-MMP, MT2-MMP, MT3-MMP 
Cell surface tissue 
transglutaminase 
Fas-receptor mediated apoptosis MMP-7 Fas ligand 
Pro-inflammatory MMP-7 (Udayakumar et al., 2003) Pro-TNFa 
Osteocleast activation MMP-7 (Lynch et al., 2005) RANK ligand 
Reduced IL-2 response MMP-9 IL-2Ra 
PAR1 activation MMP-1 (Boire et al., 2005) Protease activated receptor 1 
Generation of vasoconstrictor 
MMP-2 (Fernandez-Patron et al., 
1999) 
Big endothelin 
Conversion of vasodilator to vasoconstrictor MMP-2 (Martinez et al., 2004) Adrenomedullin 
Vasocontriction and cell growth MMP-7 (Hao et al., 2004) Heparin-binding EGF 
Neuronal apoptosis leading to neurodegeneration MMP-2 (Zhang et al., 2003) 
Stromal cell-derived factor 1a 
(SDF-1) 
Bioavailability of TGFh MMP-9 precursor of TGFh 
Thymic neovascularisation MMP-9 (Odaka et al., 2005) Collagen IV 
Hypertrophic chondrocytes apoptosis and recruitment of 
osteoclast 
MMP-9 (Odaka et al., 2005) Galactin-3 
Embryo attachment to uterine epithelia MT1-MMP (Odaka et al., 2005) MUC1, a transmembrane Mucin 
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1.6 TYPE OF MMPs 
Currently, 26 members of the MMP family have been identified in vertebrates 
of which 23 are in humans (Galis and Khatri, 2002; Johnson and Galis, 2004; Liu et 
al., 1997; Visse and Nagase, 2003). MMPs are divided into six groups: 
1. MMP-1, -8, -13, and -18 (Xenopus). These collagenases cleave interstitial 
 collagens I, II, and III at a specific site three-fourths from the N-terminus, 
 releasing 1/4 and 3/4 length fragments. They also cleave other ECM and non-
 ECM molecules.  
2. Gelatinases, including gelatinase-A (MMP-2) and gelatinase-B (MMP-9). 
 They mainly  digest denatured collagens (gelatins). They have three repeats 
 of the type II fibronectin domain inserted in the catalytic domain, which bind 
 to gelatin, collagens, and laminin (Allan et al., 1995). 
3. Stromelysins, including stromelysin-1 (MMP-3) and stromelysin-2 (MMP-
 10). MMP-3  has similar substrate specificity but higher proteolytic 
 efficiency as compared to MMP-10. 
4. Matrilysins, includingmatrilysin-1 (MMP-7) and matrilysin-2 (MMP-26, 
 endometase).  Matrilysins lack the hemopexin domain. 
5. Membrane-type MMPs (MT-MMPs), including the type-I transmembrane 
 proteins MT1-, MT2-, MT3-, and MT4-MMP (MMP-14, -15, -16, and -24), 
 and the glycosylphosphatidylinositol (GPI)-anchored proteins MT5-, and 
 MT6-MMP (MMP-17 and -25). MT1-MMP can digest type-I, -II, and III 
 collagen and other components of ECM, and can activate pro-MMP to MMP. 
6. Other MMPs, including MMP-11, -12, -19, -20, -22, -23, and -28. MMP-11 
 (stromelysin-3) differ from MMP-3 (stromelysin-1) in sequence and substrate 
 specificity. MMP-12 (metalloelastase) digests elastin and other proteins. 
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 MMP-20 (enamelysin) digests amelogenin. MMP-22 was first cloned from 
chicken fibroblasts, and a human homologue was later identified. However, its 
function and substrate remain unclear. MMP-23 (cysteine array MMP) lacks the 
cysteine switch motif in the prodomain as well as the Hpx domain which provides 
substrate specificity; instead, it has a cysteine-rich domain followed by an 
immunoglobulin-like domain. It is proposed to be a type II membrane protein 
harboring the transmembrane domain in the N-terminal part of the propeptide.  
Because it has a furin recognition motif in the propeptide (convertase cleavage site 
which  activates MMP), it is cleaved in the Golgi and released as an active enzyme 
into the extracellular space. MMP-28 (epilysin) is the latest addition to the MMP 
family (Marchenko and Strongin, 2001). 
 
1.7 ACTIVATION OF MMPS 
 Most of the MMPs constitute an amino terminal propeptide; a catalytic 
domain; and a hemopexin-like (Hpx) domain at the carboxy-terminal. The propeptide 
consists of approximately 80–90 amino acids containing a cysteine residue, which 
interacts with the catalytic zinc atom via its side chain thiol group. A highly 
conserved sequence (. . .PRCGXPD. . .) is present in the propeptide. Removal of the 
propeptide by proteolysis results in zymogen activation, as all members of the MMP 






Figure 3. Mechanism and activation of MMPs. The above diagram illustrates 
the mechanism and activation of all MMPs. (A) Ribbon diagram of human 
proMMP-1 and active pig MMP-1. The pro-domain is shown in red, catalytic 
domain in blue, the linker region in yellow, the Hpx domain in yellow, chloride 
in green, zinc ions and calcium ions in cyan. The dotted circle indicates the 
region where the catalytic and Hpx domains interact. The image was prepared 
from Brookhaven Protein Data bank entries ISU3 (proMMP-1), 1FBL(MMP-1) 
and 1GXD (proMMP-2-TIMP-2) using the PyMOL (http://www.pymol.org) 















1.8 STRUCTURAL DETAILS OF MMPs 
Most of the MMPs constitute an amino terminal propeptide, a catalytic domain 
and an Hpx like domain at the carboxy terminus (Figs. 4 and 5). The propeptide 
consists of approximately 80–90 amino acids containing a cysteine residue, which 
interacts with the catalytic zinc atom via its side chain thiol group. A highly 
conserved sequence, PRCGXPD, where ‘X’ can be any amino acid, is present in the 
propeptide. Removal of the propeptide by proteolysis results in zymogen activation, 
as all members of the MMP family are produced in a latent form. The catalytic 
domain contains two zinc ions and at least one calcium ion coordinated to various 
residues (Massova et al., 1998).  
Exceptions to this arrangement are matrilysin 1 (MMP-7), matrilysin 2 (MMP-
26) and MMP-23. They lack the linker peptide and the Hpx domain. Furthermore, 
MMP-23 has a unique cysteine-rich domain and an immunoglobulin-like domain after 
the metalloproteinase domain. The membrane-bound MMPs (MT-MMPs) are 
anchored to the plasma membrane via a transmembrane or a GPI-anchoring domain 
(Fig. 5). The gelatinases, such as MMP-2, incorporate fibronectin type II modules 












1. Collagenases (MMP-1, -8, and -13) 
 
2. Gelatinases (MMP-2 and -9) 
 
3. Stromelysins (MMP-3 and -10) 
 
4. Matrilysins (MMP-7 and -26) 
 
5. Membrane-type MMPs (MMP-14, -15, - 16 and -24) 
 
6. Membrane-type MMPs (-17 and -25) 
 
7. Other MMPs (MMP-11, -12, -19, -20, -22 and -28) 
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Cysteine array region 
 Hinge/linker 
 


















Figure 4. Classification and domain structure of the MMPs. Most MMPs 
contain a signal peptide (necessary for secretion), propeptide, a catalytic domain 
that binds zinc (Zn2+), hinge region and a Hpx carboxy (C)-terminal domain. 
Y, D, and G represent tyrosine, aspartic acid and glycine amino acids that are 
present in the catalytic domain of all collagenases. In the catalytic domain, 
MMP has a Zn2+ binding site, and a binding site for the specific substrate. 
Gelatinases contain fibronectin type II modules that improve collagen and 
gelatin degradation efficiency. Matrilysins lack Hpx domain. MT-MMP has an 
additional transmembrane binding domain. Most MMPs are secreted, but six 
membrane-type MMPs (MT-MMPs) have been identified, which are anchored 
by either a transmembrane domain or a GPI link. TM, transmembrane domain; 
GPI, glycosyl-phosphatidylinositol linker. 
 
Extracellular matrix proteases - cytokine regulation role in 
cancer and pregnancy 
 
Figure 5. Different types of domain present in structures of MMP family 
members. The domain arrangement for each MMP, sp, signal sequence; pro, 
pro-domain; cat, catalytic domain, FNII, fibronectin type II motif; L1, linker 1; 
Hpx, hemopexin domain; L2, linker 2; Mb, plasma membrane; TM, 
transmembrane domain; Cy, cytoplasmic tail; CysR, cysteine rich; Ig, 
immunoglobulin domain; GPI, glycosylphosphatidilyinositol anchor are 
provided in the above figure (Nagase et al., 2006). 
 









MMP-13 is also classified as collagenase-3 which was found by (Freije et al., 
1994). The collagenase family constitutes MMP-1, -8 and -13. collagenase 1 (MMP-
1), collagenase 2 (MMP-8) and  collagenase 3 (MMP-13) cleave type I, II and III 
collagens, respectively  (Visse and Nagase, 2003; Welgus et al., 1981). These 
metalloproteinases are expressed in a variety of cells and tissues. Interstitial 
collagenolysis is essential in many biological processes such as morphogenesis (Gross 
and Lapiere, 1962), wound healing (Pilcher et al., 1999), and bone remodelling 
(Delaisse et al., 2000; Zhao et al., 1999). Unbalanced collagenolysis is associated with 
diseases such as arthritis, cancer, atherosclerosis, aneurysm, and fibrosis (Delaisse et 
al., 2000; Woessner, 1998). All collagenolytic MMPs cleave type I–III collagens at 
specific peptide bonds located 3/4 away from the N terminus and generate the 
characteristic 3/4 and 1/4 fragments, which are then denatured at body temperature 
and further degraded by collagenases, gelatinases and other nonspecific proteinases. 
In this work, we studied MMP-13, a specific target for arthritis and cancer. 
Collagenase-3 (MMP-13) is a matrix metalloproteinase involved in human breast 
cancer pathology and in arthritic processes. It is a zinc dependent protease which 
catalyses the cleavage of type II collagen, the main structural component of articular 
cartilage (Wu et al., 2005). It is capable of cleaving the peptide bond between residues 
775 and 776 in all three strands of the  mature triple helical type II collagen molecule 
(Li et al., 1995). MMP-13 is expressed in articular cartilage and joints of osteoarthritis 
(OA) and rheumatoid arthritis (RA), respectively, but not in normal adult tissues 
(Johnson et al., 2007; Vincenti and Brinckerhoff, 2002). Preclinical data implicate 
human MMP-13 as the direct cause of irreversible cartilage damage in arthritic 
conditions (Billinghurst et al., 1997; Johnson et al., 2007; Kim et al., 2005; Neuhold 
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et al., 2001). This is supported by the findings that over expression of MMP-13 
induce OA in transgenic mice, its mRNA expression co-distributes with type II 
collagenase activity in osteoarthritic cartilage, and that an inhibitor of MMP-13 has 
been shown to disrupt the degradation of explanted human osteoarthritic cartilage.  
 In the arthritic syndromes, the expression of MMP-13 is elevated in response 
to the inflammatory signals by leukocytes and other immune cells, in particular 
interleukin 1 (IL-1) and tumour necrosis factor α (TNF-α) (Vincenti and Brinckerhoff, 
2002). The increased levels of MMP-13 result in an imbalance in their regulation by 
tissue inhibitors of metalloproteinases (TIMPs), thus resulting in the disease state 
(Gomis-Ruth et al., 1997).  
   
1.9.1 Catalytic domain of MMP-13 - limitation for selective MMP drugs 
Early broad spectrum MMP inhibitors directed towards the zinc region (Fig. 6) 
of the catalytic domain (inhibitors exploiting the hydroxamate function as a zinc 
binding group) have been ineffective because of their dose limiting toxicity in the 
form of musculoskeletal syndrome (MSS), characterised by joint stiffness and 
inflammation (Baragi et al., 2009). Conversely, specific inhibitors targeting the non-
zinc region of the catalytic domain have been shown to effectively reduce cartilage 
damage (Johnson et al., 2007). Recent studies have, therefore, focused on the search 
for selective inhibitors of MMP-13 (Baragi et al., 2009; Piecha et al., 2009; Schnute et 
al., 2010). The Hpx domain of the protease (Ezhilarasan et al., 2009; Lauer-Fields et 
al., 2009; Mantuano et al., 2008), which is critical for substrate specificity, represents 
an alternative target for the search of such inhibitors. 
Until now, most investigations have focused on the catalytic domain, in an 
attempt to unravel the determinants of substrate specificity at and around the active 
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site cleft, also with the aim to obtain information useful to design inhibitors that can 
be selective for specific MMPs (Kridel et al., 2002; Pavlovsky et al., 1999; Terp et al., 
2002). From the structural point of view, the currently available results in the 
literature on the catalytic domain provide a much extended picture of its properties 
also across different MMPs. 
  
 
Figure 6. Inhibitor is binding to zinc and non-zinc regions of MMPs. Selective 
inhibitor binding to the non-zinc region of catalytic domain of MMP. A ribbon 
diagram illustrating the unexpected binding mode for MMP-13 
acetohydroxamic acid within the specificity loop of the enzyme (represented as 
non-zinc region and circled in white color). Whereas zinc and calcium ions were 
depicted in magenta and green respectively, this has been represented as zinc 
binding region circled in white color. In the following reference it clearly states 
that targeting non-zinc region of MMP still causes MSS syndrome and hence 
developing inhibitors against Hpx domain could be an alternative strategy for 






 However, it is more and more appreciated that a deeper understanding of the 
structural features of the other domains and of the higher multidomain construct is 
needed (Overall, 2002). Indeed, from the drug designing point of view , targeting sites 
contributing to the interaction with the substrates but far from the active site could be 
a good strategy to enhance the selectivity of candidate drugs (Overall and Lopez-Otin, 
2002). 
 
1.9.2 Hemopexin (Hpx) domain of MMP-13 for selectivity of MMP drugs 
The function of the Hpx domain of MMPs spans from a fairly restricted role in 
substrate recognition to a wide range of protein interactions. This role is consistent 
with the protein interactions of the Hpx domain of other proteins. The Hpx domain of 
MMPs has been suggested to facilitate activation, inhibition by TIMPs, cell surface 
localization and endocytosis (Gomis-Ruth, 2003; Piccard et al., 2007). Consequently, 
the MMP-13 protease has been a target for the inhibition of the progression of OA, 
RA and cancer. 
 All MMPs in general have a similar domain architecture, namely an N-
terminal signal sequence for secretion, a propeptide domain to maintain latency in cell 
signalling, a catalytic domain containing the catalytic zinc binding motif, a linker 
region that links the catalytic domain with the c-terminal four bladed propeller 
structured Hpx domain (Gomis-Ruth et al., 1996). The catalytic domain of these 
MMPs alone is unable to cleave triple helical collagens without the Hpx domain 
(Clark and Cawston, 1989; Hurst et al., 2004; Knauper et al., 1993; Knauper et al., 
1997; Murphy et al., 1992; Ohuchi et al., 1997). Furthermore, the removal of the Hpx 
domain from MMP-1, -8 and -13, which belong to the collagenase family, has been 
shown to result in a loss of collagenolytic activity (Manka et al., 2012) . Thus, the 
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Hpx domain in the C-terminal region maintains the specificity of the collagenase 
family MMPs by affecting substrate binding (Li et al., 1995). The mechanism of 
cleavage is represented in Fig. 7. The Hpx domain of the protease (Ezhilarasan et al., 
2009; Lauer-Fields et al., 2009; Mantuano et al., 2008), which is critical for substrate 
specificity, represents an alternative target for the search of such inhibitors. 
 
 
Figure 7. Mechanism of cleavage of triple helical collagen.The scheme 
showing the proposed involvement of the C-terminal domain (CTD) in specific 
clevage of triple-helical collagen fibres by full-length collagenases. After the 
binding of the triple-helical collagen substrate, the CTD probably folds with its 
entry-side over the catalytic site of the catalytic domain, trapping the collagen 
substrate (Manka et al., 2012). The Hpx and catalytic domains are represented 
as cartoon and the Hpx domain is shown in purple color; whereas the catalytic 
domain containing the α-helices and β-sheets are shown in magenta and purple 
colours representively. And the triple helical collagen is represented in stick. 









 In this study, we applied a cheminformatics-based drug design approach to (i) 
define the putative functional residues of MMP-13 Hpx domain (ii) identify and 
characterize the ligands that bind to these residues and (iii) assess the selectivity of 
these ligands by testing their cross-reactivity to other collagenase family members, 
MMP-1 and -8 (Table 2). Such screened, selected and potentially specific inhibitors 
can then be tested by experiments to validate their specificity to MMP-13 and their 





Table 2. Structures of domains and full length protein of several MMPs. 
MMP13 Type of domain MMP1 Type of domain  MMP8 Type of domain 
1cxv  catalytic domain  1AYK  catalytic domain   1A85  catalytic domain  
1eub  catalytic domain  1CGE  catalytic domain   1A86  catalytic domain  
1fls  catalytic domain  1CGF  catalytic domain   1BZS  catalytic domain  
1fm1  catalytic domain  1CGL  catalytic domain   1I73  catalytic domain  
1pex  hemopexin  1FBL  catalytic domain  hemopexin domain  1I76  catalytic domain  
1xuc  catalytic domain  1HFC  catalytic domain   1JAN catalytic domain  
1xud  catalytic domain  1MNC  catalytic domain   1JAO  catalytic domain  
1xur  catalytic domain  1SU3  catalytic domain  hemopexin domain  1JAP  catalytic domain  
1you  catalytic domain  2AYK  catalytic domain   1JAQ  catalytic domain  
1ztq  catalytic domain  2CLT  catalytic domain  hemopexin domain  1JH1  catalytic domain  
2d1n  catalytic domain  2TCL  catalytic domain   1JJ9  catalytic domain  
2e2d  catalytic domain  3AYK  catalytic domain   1KBC  catalytic domain  
2ow9  catalytic domain  4AYK  catalytic domain   1MMB  catalytic domain  
2ozr  catalytic domain  966C  catalytic domain   1MNC  catalytic domain  
2pjt  catalytic domain  3SHI catalytic domain   1ZP5  catalytic domain  
456c  catalytic domain  2JOT catalytic domain   1ZS0 catalytic domain  
830c  catalytic domain  4AUO catalytic domain  hemopexin domain  1ZVX  catalytic domain  
1UMS catalytic domain     2OY4  catalytic domain  
3ELM catalytic domain     3DNG  catalytic domain  
3I7G catalytic domain     3DPE  catalytic domain  
3I7I catalytic domain     3DPF  catalytic domain  
3KRY catalytic domain     2OY2 catalytic domain  
3KEC catalytic domain     2OY4  catalytic domain  
3KEJ catalytic domain     3TT8 catalytic domain  
3KEK catalytic domain       
3LJZ catalytic domain       
2YIG catalytic domain       
3O2X catalytic domain       
4A7B catalytic domain       
3TVC catalytic domain       
4H30 catalytic domain       
4I03 catalytic domain  
     The shaded entries have been used in this project to check the cross reactivity between MMP-1, -8 and -13 corresponding to their 
functional amino acid residues. 
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1.10 DRUG DESIGNING 
Development of a drug involves iterative steps of identifying new therapeutics 
based on a particular biological target (Madsen et al., 2002). A drug is most 
commonly an organic small molecule that activates or inhibits the function of a 
biomolecule such as a protein which in turn results in a therapeutic benefit to a 
patient. In most cases, drug designing involves the development of small molecules 
that are complementary in shape and charge to a biomolecular target with which they 
interact. Drug designing frequently relies on computational techniques (Cohen, 1996).  
 The modern day drug discovery pipeline is outlined in Fig. 8. The first step is 
to identify biological targets such as hormone, receptor, enzyme, peptide and nucleic 
acid. Then screening public or specifically compiled databases of hundreds of 
thousands of organic or synthetic compounds will be undertaken in a matter of days to 
weeks. It is always advantageous to begin the screening with established drug 
compounds. This will enable a developer to rapidly prototype a candidate ligand 
whose chemistry is well known and within the intellectual property of the developer. 
The initial successful hits are called lead compounds. The interaction of a lead 
compound with its target can be verified by X-ray crystallography, if possible. From 
this point onward, a cycle of iterative chemical refinement and testing continues until 




Figure 8. Sequential procedure and steps involved in drug development. 
 
 Combinatorial chemistry and structure based validation assist the refinement 
process significantly. This is a very powerful technique that chemists employ to aid in 
the refinement of a lead compound. It is a synthetic tool that enables chemists to 
rapidly generate thousands of lead compound derivatives for testing. A scaffold is 
employed that contains a portion of the ligand that remains constant. Subsite groups 
(shown in red, green, and blue) are potential sites for derivatization. These subsites 
are then reacted with combinatorial libraries to generate a multitude of derivative 
structures, each with different substituent groups. One can see how a vast number of 
compounds can be generated as a result of the combinatorial process. If a scaffold 
contains three derivatization sites and the library contains ten groups per site, 
theoretically 1000 different combinations are possible as shown in Fig. 9. By carefully 
selecting libraries, based upon the study of the active site, we can target the 






Figure 9. An example to illustrate steps involved in combinatorial chemistry 
based design of ligands. An example of a drug molecule from a database is 
presented in the above figure. Using combinatorial chemistry, where the 
backbone scaffold of the drug molecules has been slightly modified with an 
additional side chain of benzene rings that is in blue colour.  
 
 Furthermore, the lead compounds are tested for its toxicity on normal cells 
using in vivo studies in laboratory conditions, followed by clinical trials. Clinical trials 
involving new drugs are commonly classified into four phases. Each phase of the drug 
approval process is treated as a separate clinical trial. The drug-development process 
will normally proceed through all four phases over many years. If the drug 
successfully passes through Phases 1, 2, and 3, it will usually be approved by the 
national regulatory authority for use in the general population. 
Phase 1: Screening for safety. In Phase 1 trials, researchers test an experimental drug 
or treatment in a small group of people (20-80) for the first time to evaluate its safety, 
determine a safe dosage range, and identify side effects. Each phase has a different 




Phase 2: Establishing the testing protocol. In Phase 2 trials, the experimental 
treatment is given to a larger group of people (100-300) to see if it is effective and to 
further evaluate its safety. 
Phase 3: Final testing. In Phase 3 trials, the treatment is given to large groups of 
people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to 
commonly used treatments, and collect information that will allow it to be used 
safely. 
Phase 4: Post approval studies. In Phase 4 trials, post marketing studies delineate 
additional information, including the treatment's risks, benefits, and optimal use. 
Before pharmaceutical companies start clinical trials on a drug, they conduct 
extensive preclinical studies. 
 
1.11 COMPUTER-AIDED DRUG DESIGN/CHEMINFORMATICS 
Computer-aided drug design/Cheminformatics is typically carried out by 
computationally docking sets of compounds into a rigid model of the active site of a 
protein. In the past, docking methods were primarily used to identify small sets of 
molecules (10–100), which would be active against a single target. More recently, 
docking methods have been used to prioritize combinatorial libraries and create 
screening libraries focused on specific gene families/macromolecular targets. 
Although docking is a relatively well-developed technique, it still suffers from several 
limitations. One limitation is that docking studies are typically carried out using a 
rigid target model. Although a few docking methods allow a certain degree of side-
chain flexibility, these programs are currently unable to model loop movements or 
induced-fit effects, which are found in many systems. The most prominent limitation 
of docking programs results from the scoring functions that they use to predict 
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binding affinity. Although a great deal of progress has been made in this field, an 
accurate and generally applicable scoring function is still not available (Ajay and 
Murcko, 1995; Charifson et al., 1999; Muegge and Rarey, 2001). The lack of quality 
in scoring function can end up being less crucial when the objective is to enrich a 
screening library, rather than to identify single compounds. When designing a 
screening library targeted to an entire gene family, it can be more important to 
identify molecules with a certain shape or a set of key features. 
 
1.12 STRUCTURE BASED DRUG DESIGN (SBDD) 
Structure-based drug design (or direct drug design) relies on the knowledge of 
the three dimensional structure of a biological target obtained through methods such 
as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy (Leach 
and Jhoti., 2007). If an experimental structure of a target is not available, it may be 
possible to create a homology model of the target, based on the experimental structure 
of a related protein. Using the structure of the biological target, candidate drugs that 
are predicted to bind with high affinity and selectivity may be designed using 
interactive graphics and the intuition of a medicinal chemist. Alternatively various 
automated computational procedures may be used to suggest new drug candidates. 





Figure 10. Integration of structural and informatics methods. The diagram 
illustrates how different computational approaches complement each other in 
the context of structure-based drug design (Tang and Marshall, 2011). 
 
Drug designing that relies on the knowledge of the three-dimensional structure 
of a biomolecular target is known as structure-based drug design (SBDD). In addition, 
the use of structural information in virtual ligand screening (Oprea and Matter, 2004; 
Shoichet, 2004) and SBDD (Scapin, 2006) can potentially reduce the numbers of 
compounds that need to be evaluated, and lead to new directions for synthetic 
optimization. Current methods for structure-based drug designing can be divided 
roughly into two categories. The first category is about “finding” ligands for a given 
target which is usually referred as database searching. In this case, a large number of 
potential ligand molecules are screened to find those fitting the binding pocket of the 
target (Fig. 11). This method is usually referred as ligand-based drug design. The key 
Experimental structure determination  
(X-ray crystallography, NMR)
3D protein structures (templates for 
model building)
Comparative modelling
Sequences of novel 
therapeutic targets
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compounds on 3D structures of 
targets)
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(design of combinatorial libraries 
taking 3D constraints of binding sites 
into account)
Hits
Structure-based analog design 
(design of modified hits using 3D 





advantage of database searching is that it saves synthetic effort to obtain new lead 
compounds. Another category of structure-based drug design methods is about 
“building” ligands, which is usually referred as receptor-based drug design. In this 
case, ligand molecules are built up within the constraints of the binding pocket by 
assembling small pieces in a stepwise manner. These pieces can be either individual 
atoms or molecular fragments. The key advantage of such a method is that novel 
structures, not contained in any database, can be suggested (Jorgensen, 2004; R. et al., 
2000; Schneider and Fechner, 2005). 
  Structure-based drug design (SBDD) has recently proven to be successful in 
the design of the following drugs which are already in clinical trials, of medically 
relevant proteins in complex with compounds developed during the drug discovery 
process. 
1. Dorzolamide (Glaucoma treatment) 
2. Saquinavir, Indinavir, Ritonavir, Nelfinavir (HIV therapy) 
3. Neuroaminidase inhibitors (anti-influenza) 
4. COX-2 inhibitors (anti inflammatory) 
5. Phospholipase A(2) inhibitors (anti inflammatory)  
 
 
Figure 11.  Docking example of HIV and its inhibitor ‘Indinavir’. This example 
showing an antagonist named ‘Indinavir’ of HIV protease presented in virtual 
space using computer modelling and graphics in PyMoL as an example for 
structure based drug design. The active site residue Asp25 which is involved in 
interaction with drug Indinavir (the drug is represented in CPK representation). 
The above figure was obtained from Autodock tutorial. 
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 These compounds go through numerous iterations as they progress towards the 
clinic. In an industrial environment, where multiple projects are being worked 
simultaneously, with each of them likely having multiple compound series, the 
number of total complex required structures can be very high (hundreds per year). 
Also, the success ratio of crystals with the ligand to harvested crystals will be very 
small. The efficiency of the process can be improved only by using bioinformatics 
tools for sample tracking and automation for sample handling (Gyorgy, 2012).  
 
1.13 ACTIVE SITE IDENTIFICATION 
Active site identification is the first step in this program. It analyzes a protein 
to assign a suitable drug binding pocket, derives key interaction sites within the 
binding pocket, and then prepares necessary data for ligand-fragment link. The basic 
inputs for this step are the 3D-structure of the protein and a pre-docked ligand, as well 
as their atomic properties. Both ligand and protein atoms need to be classified and 
their atomic properties should be defined, basically, into four types: hydrophobic 
atoms (all carbons); H-bond donor (oxygen and nitrogen atoms bonded to hydrogen 
atoms); H-bond acceptor (oxygen and sp2 or sp hybridized nitrogen atoms with lone 
electron pairs); polar atom (oxygen and nitrogen atoms that are neither H-bond donor 
nor H-bond acceptor, sulphur, phosphorus, halogen, metal, and carbon atoms bonded 
to hetero-atoms). 
The space inside the ligand binding region would be studied with virtual probe 
atoms of the above four types so that the chemical environment of all spots in the 
ligand binding region can be known. This will suggest what kind of chemical 




1.14 VIRTUAL SCREENING 
Virtual screening is a computational method for identifying lead compounds 
from large and chemically diverse compound libraries. This computational method is 
valuable for discovering lead compounds in a faster, more cost-efficient, and less 
resources-intensive manner compared to experimental methods such as high-
throughput screening (1-4). The virtual screening could be separated into two steps: 
docking and scoring (Tang and Marshall, 2011) .  
 High-throughput screening is the most common experimental method used to 
identify lead compounds. Because of the cost, time, and resources required for 
performing high-throughput screening for compound libraries, the use of alternative 
strategies is necessary for facilitating lead discovery. Virtual screening has been 
successful in prioritizing large chemical libraries to identify experimentally active 
compounds, serving as a practical and effective alternative to high-throughput 
screening. Methodologies used in virtual screening, such as molecular docking and 
scoring, have advanced to a point where they can rapidly and accurately identify lead 
compounds in addition to predicting native binding conformation.  
  
1.15 ADSORPTION, DISTRIBUTION, METABOLISM AND 
 EXCRETION (ADMET) 
While virtual screening was expected to generate new drugs easily, just by 
virtue of the sheer size of the available libraries, in fact, things were not that straight 
forward (Lahana, 1999). In the early days, many large sets of biologically inactive 
molecules were tested, most often as ill-defined mixtures. Library composition has 
subsequently been significantly influenced by Chris Lipinski, who formulated simple 
rules for predicting which compounds would support useful bioavailability (Lipinski 
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et al., 2001). The bioavailability of drug molecules could be analysed by its 
physicochemical properties using Lipinski’s rule of five.  
 According to Lipinksi's 'rule of five' (Lipinski et al., 2012), drug candidates 
should have a molecular mass below 500 Daltons, a lipophilicity below Log P = 5, 
and contain no more than 5 hydrogen bond donors and no more than 10 oxygen and 
nitrogen atoms. Furthermore, poor passive absorption is to be expected if two or more 
of these conditions are violated. As an alternative to the Lipinski rules, polar surface 
area (Ertl et al., 2000) or VolSurf parameters (Cruciani et al., 2000) can be used to 
predict oral absorption (Jorgensen, 2004; Leach and Jhoti., 2007; Scapin, 2006; 
Shoichet, 2004) and blood–brain barrier penetration (Cruciani et al., 2000; Kelder et 
al., 1999). The flexibility of molecules has been recognized as another factor 
influencing bioavailability (Veber et al., 2002). 
  
Figure 12. Virtual screening process 
  
 Violation of the Lipinski rules was indeed the main reason for failure of early 
combinatorial libraries, and the application of the rules significantly aided 
100000 
• Available from public database 
1000 
• Screened and narrowed down to ‘n’ number of 
molecules based on pharmacokinetics properties 
(Lipinskis rule of five) using computational techniques 
25 
• Compounds  that  have better binding energy than 
known 
7 




improvements. In this context, two investigations are most often cited (Bohm, 1994), 
which correlated about 40% of failures in clinical development with inappropriate 
pharmacokinetics, that is, a lack of sufficient oral efficacy. Correspondingly, 
absorption, distribution, metabolism and excretion (ADME) parameters are now 
considered to be key factors in drug development. The sequential analysis of virtual 
screening is presented below in Fig. 12.  
 
1.16 DOCKING 
The docking process involves the prediction of ligand conformation and 
orientation (called posing) within a targeted binding site (Figs. 13 and 14). In general, 
there are two aims of docking studies: accurate structural modelling and correct 
prediction of activity. However, the identification of molecular features that are 
responsible for specific biological recognition, or the prediction of compound 
modifications that improve potency, are complex issues that are often difficult to 
understand and even more so to simulate on a computer. 
In view of these challenges, docking is generally devised as a multi-step 
process in which each step introduces one or more additional degrees of complexity 
(Brooijmans and Kuntz, 2003). The process begins with the application of docking 
algorithms that place (The process of determining whether a given conformation and 
orientation of a ligand fits the active site. This is usually a fuzzy procedure that 
returns many alternative results) small molecules in the active site. This in itself is 
challenging, as even relatively a simple organic molecule can contain many 
conformational degrees of freedom. 
Sampling these degrees of freedom must be performed with sufficient 
accuracy to identify the conformation that best matches the receptor structure, and 
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Figure 13. Schematic diagram 
illustrating the docking model. The 
diagram shows a small molecule ligand 
(brown color) to a protein receptor (green 
color) to produce a complex. 
 
Figure 14. A docked pose of 
a ligand and protein receptor 
in its active site. The 
compound is displayed in 
sticks and the macromolecule 
is displayed by surface 
representation by use of 
PyMOL. 
 
 Algorithms are complemented by scoring functions (both posing and ranking 
involve scoring. The pose score is often a rough measure of the fit of a ligand into the 
active site. The rank score is generally more complex and might attempt to estimate 
binding energies) that are designed to predict the biological activity through the 
evaluation of interactions between compounds and potential targets. Early scoring 
functions evaluated compound fits on the basis of calculations of approximate shape 
and electrostatic complementarities. Relatively simple scoring functions continue to 
be heavily used, at least during the early stages of docking simulations. Pre-selected 
conformers are often further evaluated using more complex scoring schemes with a 
more detailed treatment of electrostatic and van der Waals interactions, and inclusion 
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of at least some solvation or entropic effects (Gohlke and Klebe, 2002). It should also 
be noted that ligand binding events are driven by a combination of enthalpic and 
entropic effects, and that either entropy or enthalpy can dominate specific 
interactions. This often presents a conceptual problem for contemporary scoring 
functions (discussed below), because most of them are much more focused on 
capturing energetic than entropic effects. 
 In addition to the problems associated with scoring of compound 
conformations, other complications exist that make it challenging to accurately 
predict binding conformations and compound activity. These include, among others, 
limited resolution of crystallographic targets, inherent flexibility, induced fit or other 
conformational changes that occur on binding, and the participation of water 
molecules in protein–ligand interactions.  
 
1.17 SCORING METHOD 
 Structure-based drug designing attempts use the structure of proteins as a basis 
for designing new ligands by applying accepted principles of molecular recognition. 
The basic assumption underlying structure-based drug designing is that a good ligand 
molecule should bind tightly to its target. Thus, one of the most important principles 
for designing or obtaining potential new ligands is to predict the binding affinity of a 
ligand to its target and use it as a criterion for selection. 
 A method was developed by Böhm (Bohm, 1994) to develop a general-
purpose empirical scoring function in order to describe binding energy. The following 
‘master equation (Eq.1)’ was derived: 
 Gbind        Kd 
Kd 
                    




 Gbind =  Gdesolvation +  Gmotion +  Gconfiguration +  Ginteraction  ....Eq. 1 
 
 Where: desolvation  enthalpic penalty for removing the ligand from solvent; 
motion  entropic penalty for reducing the degrees of freedom when a ligand binds 
to its receptor; configuration  conformational strain energy required to put the 
ligand in its "active" conformation; interaction enthalpic gain for "resolvating" the 
ligand with its receptor. 
 The basic idea is that the overall binding free energy can be distributed into 
independent components that are known to be important for the binding process. Each 
component reflects a certain kind of free energy alteration during the binding process 
between a ligand and its target. The master equation is the linear combination of these 
components. According to the Gibbs free energy equation, a relationship between 
dissociation equilibrium constant, Kd, and the components of free energy can be built. 
 Various computational methods are used to estimate each of the components 
of the master equation. For example, the change in polar surface area upon ligand 
binding can be used to estimate the desolvation energy. The number of rotatable 
bonds, frozen upon ligand binding, is proportional to the motion term. The 
configuration or strain energy can be estimated using molecular mechanics 
calculations. Finally the interaction energy can be estimated using methods such as 
the change in non-polar surface, statistically derived potentials of mean force and the 
number of hydrogen bonds formed. In practice, the components of the master 
equation are fit to experimental data using multiple linear regression. This can be 
achieved with a diverse training set, including many types of ligands and targets to 
produce a less accurate but more general ’global’ model or a more restricted set of 
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ligands and targets to produce a more accurate but less general ’local‘  model (Clark 
et al., 2002; Gohlke et al., 2000; Wang et al., 2002).  
 Drug discovery pipelines in pharmaceutical companies are fuelled by HTS as 
one of the major sources of new hit-to-lead candidates. This is a direct consequence of 
our lack of knowledge about function-determining features of desired ligand 
molecules in the early stages of the discovery process. We expect de novo designing 
to increasingly become a complementary strategy to high throughput screening (HTS) 
through a number of routes: by suggesting new chemical entities that are designed 
taking into consideration several aspects of lead- and drug-likeness and synthetic 
accessibility; by making full use of pre-existing knowledge, such as reference ligands 
or receptor models; and by facilitating the designing of activity-enriched screening 
sets with increased hit rates. 
 As experimental methods, such as X-ray crystallography and nuclear magnetic 
resonance (NMR), develop, the amount of information concerning 3D structures of 
biomolecular targets has increased dramatically. In parallel, the information about 
structural dynamics and electronic properties of ligands has also increased. This has 










CHAPTER 2. X-RAY CRYSTALLOGRAPHY 
 
2.1 CRYSTALLOGRAPHY 
Usually, the major problem in a crystallographic study is getting a diffracting 
quality protein crystal. Self periodic assembly of protein molecules, with 
intermolecular forces between them, leads to crystal packing and formation of protein 
crystals. In simple, a crystal is an anisotropic, homogeneous body consisting of a 
three-dimensional periodic ordering of atoms, ions or molecules. The stability and 
diffraction capability of crystals depend upon the extent of the intermolecular forces 
between individual molecules and contact/volume ratio. Formation of a well ordered 
crystal needs proper packing of molecules in a limited space (Chernov, 2003; 
Helliwell, 2005). A well formed crystal produces diffraction images when placed in 
an X-ray beam. We use a computer to produce the view of the arrangement of atoms 
(real lattice) from diffraction images (reciprocal lattice). 
 
2.1.1 The unit-cell  
 The simplest repeating unit in a crystal is known as a unit-cell (Buerger, 
1966). Three dimensional crystal packing can be defined by an ordered stacking 
arrangement of unit-cells. Basically a unit cell can be explained with three vectors a, b 
and c and interaxial angles of α, β and γ. A unit-cell is classified into one of seven 
different forms on the basis of symmetry which is explained in Fig. 15. The most 
important thing to be noticed is that the geometric condition of a unit-cell is not 
sufficient to define its associated crystal system. For example, during data processing, 
be warned that a unit-cell may have all three angles very close to 90º and yet the 




Figure 15. Seven basic unit-cells. Figure obtained from BL5021 lecture notes. 
 
2.1.2 Lattices, planes and indices 
If each unit-cell in a crystal is represented by a point, then the array of these 
points is called a lattice. A lattice can be primitive, designated as P, when one lattice 
point is present per unit-cell. However, in some cases, it is more advantageous to 
encompass smaller unit-cells into a larger unit-cell, thereby enclosing more lattice 
points in the bigger unit-cell. The arrangement of these lattice points, in perspective of 




for ac face centering and C for ab face centering. If all the faces are centered, the 
designation is F, and if the unit-cell body is centered, it is designated as I. The 
collection of 14 possible crystallographic lattices in Fig. 16 was first described by 
French physicist Auguste Bravais in 1850.  
 Mineralogist William Hallowes Miller in 1839 introduced imaginary planes 
within a unit-cell and defined them by using Miller indices. The indices hkl identify a 
particular set of equivalent and parallel planes. 
 Index h indicates the number of planes per unit-cell in the x direction while k 
and l specify the number of planes in the y and z direction, respectively. An example 
is shown in Fig. 17. The perpendicular distance d between adjacent lattice planes is 
related to the (shortest) reciprocal lattice vector orthogonal to the planes by Equation 
1.1. 





Figure 16. The 14 Bravais lattices. Figure adapted from Charles Kittel, 
Introduction to solid state physics, 7th ed. 
 
 
Figure 17. Miller indices of some planes in a unit-cell. “Figure adapted from 
NYU Chemistry Lecture Notes”. 
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2.2 SYMMETRY OPERATION, POINT GROUPS AND SPACE GROUPS 
Symmetry can be defined as the precise and balanced operations that can 
generate an identical or similar crystallographically indistinguishable image of an 
object. Pseudo symmetry differs by having a copy of a similar object in place after an 
operation which is not crystallographically identical. The main symmetry operations 
present in a crystal system are translation, rotation and reflection,  
In the rotational symmetry operation, only rotational angles of 60, 90, 120, 
180 and 360° are allowed. The applied rotation angle is represented by an integer n (n 
= 1, 2, 3, 4, 6) where n is the number of times a molecule is rotated within 360°, or 
360/n).   
Inversion is a symmetry element that creates the image of an object, with 
respect to a point. The symbol of inversion is ‘i’. Every bit of an object is inverted 
with respect to the reference point and an image is created. In Fig. 18 the object L-
glycine gives rise to D-glycine, through the inversion symmetry, acting at the point O. 
Inversion creates an enantiomer (two objects that look alike but differ in the 
handedness; eg: the left hand and the right hand). Enantiomers cannot be 








Figure 18.  An example showing inversion symmetry. L-amino acid (right) is 
inverted to give D-amino acid (figure from BL5215 lecture notes) 
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 Rotation is a symmetry operation, where multiple copies of the same object 
are arranged to form a well-ordered pattern. Four birds in Fig. 19 show how 
they are arranged around a line. The line is called the axis of rotation. The order 








Figure 19.  Rotation symmetry (figure from BL5215 lecture notes) 
 
 In the above case, n is 4. In other words, we can say that the four birds are 
related by a 4-fold axis of rotation. The angular distance between two adjacent birds is 
90 (360/4). The distance of all the birds from the axis of rotation must be same. Even 
though any number of identical copies of an object can be arranged in a circular 
fashion, only 1, 2, 3, 4 and 6 fold rotations are allowed in crystallography. Unlike 
inversion, the object and its images generated by a rotation are superimposable. 
 Reflection is also an operation that generates an image from an object. The 
symbol of reflection is ‘m’. A reflection also generates two enantiomers. The line 
connecting any point of an object and its corresponding point in the reflection image 
is perpendicular to the plane of reflection.  
When a molecule moves along a, b or c of the unit-cell, translational 
symmetry is applied. The combination of rotation and translation gives the screw 
symmetry For example, in the two-fold screw operation; a molecule is first rotated 
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180° and then translated half of the unit-cell length in the positive direction of the 
axis. Similarly, the combination of reflection and translation generate glide symmetry. 
 Combinations of the basic symmetry operations give more symmetry 
operations. Point groups describe the assembly of symmetry elements, without any 
translation, in the unit-cell. For example point group 222 (the three digits represent 
operations carried out on a, b and c axis, respectively), has three 2-fold rotations. The 
concept of space group was first enumerated by Fyodorov (1891). Space groups 
provide detailed information of 3-dimensional arrangement of molecules, including 
translation, in the unit-cell. For example, space group has two fold screw operations 
along both a and b axes and a two-fold rotation along the c axis. The unit-cell 
arrangement in the crystal is primitive as indicated by ‘P’. In this way, all 230 space 
groups, tabulated in the International Tables of Crystallography (Hahn, 1998), arise as 
a result of the combination of 32 point groups, 14 Bravais lattices of the 7 lattice 
systems and translation symmetry (Buerger, 1956). 
Mirror and inversion symmetry operations are not applicable to protein 
molecules because applying these operations will cause the interchange of right and 
left handedness of the molecule. This will warrant the presence of D-amino acids in 
protein molecules, which do not exist in nature. 
 
2.3 BRAGG’S LAW: THE CONDITION THAT PRODUCES 
 DIFFRACTION 
Bragg’s law is a condition for diffraction by a crystal when electromagnetic 
radiation of wavelength that is comparable to atomic spacing is allowed to be incident 
on a crystalline sample, scattered and undergoes a constructive interference. For a 
crystalline solid, W.L. Bragg showed that a set of parallel planes with indices hkl and 
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interplanar spacing dhkl produces a diffracted beam when X-rays of wavelength λ 
impinge upon the planes at an angle θ and reflected, also at the same angle, only if θ 
meets the condition 
2dhkl sinθ = nλ …. (1.2) 
 
Where n is an integer (Rhodes, 2000). 
 
Figure 20. Bragg’s law that governs diffraction. Figure adapted from Rhodes, 
2000. 
  
 The two planes (Fig. 20) represent two parallel rows of lattice points with 
interplanar spacing dhkl. Two rays R1 and R2 are reflected from them at an angle θ. 
Lines AC are drawn from the point of reflection A of R1, perpendicular to ray R2. If 
ray R2 is reflected at B, then the diagram shows that R2 travels the same distance as 
wave 1 plus an additional distance of 2BC. Because AB, in triangle ABC, is 
perpendicular to the atomic plane, and AC is perpendicular to the incident ray, angle 
CAB equals θ, the angle of incidence (two angles are equal if corresponding sides are 
perpendicular). Because ABC is a right-angled triangle, the sine of angle θ is BC/AB 
or BC/dhkl. Thus BC equals dhkl sinθ, and the additional distance 2BC travelled by ray 
R2 is 2dhkl sinθ. If this difference in path length for rays reflected from successive 
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planes is equal to an integral number of wavelengths of the impinging X-rays 
(satisfying Equation 1.2), then the rays are in phase with each other, interfering 
constructively to produce a strong diffracted beam. The same condition can be applied 
for neutron and electron diffraction processes also. 
 
2.4 BRAGG’S LAW IN RECIPROCAL LATTICE 
The X-ray diffraction pattern from a crystal consists of reflections (spots) in an 
orderly array on film. The angle of diffraction has a simple inverse relationship with 
the spacing of unit-cell in the crystalline lattice. The arrangement of reflections which 
emanate from a crystal (recorded on film) is referred to as a reciprocal lattice. A 
reciprocal lattice is generated as explained in Fig. 21. Take O as the origin in a crystal 
lattice. Draw one plane for each of the sets (110), (120) and so forth, whose 
interplanar distances will be d110, d120 and so on, respectively. From the origin, draw a 
line normal to the (110) plane. The point at a distance, 1/d110, on this line will define 
the reciprocal lattice point 110. Do the same for (120) and so on. Thus the new points 
define a lattice, with the chosen origin. This new lattice is the reciprocal lattice. If the 
real unit-cell angles α, β and γ are 90°, the reciprocal unit-cell has axes a* lying along 





 are defined. If the axial lengths are expressed in Angstroms, 
then the reciprocal lattice spacing is in the unit 1/Å or Å
-1




Figure 21. The reciprocal lattice. Figure adapted from (Buerger, 1956). 
 
2.5 THE EWALD SPHERE 
Consider a circle of radius r, with points B and C lying on the circumference. 
 
Figure 22. The Ewald Sphere. 
 
By trigonometry,  
 
If this geometry is constructed in reciprocal space, then it has some important 
implication. The radius can be set to 1/λ, where λ is the experimental wavelength. If O 
is the (0 0 0) reciprocal lattice point, and B is a general point (h k l), then the distance 
48 
 
OB is 1/dhkl = Shkl The reciprocal vector between the points, S, increases in magnitude 
with increasing 2θ. 
Hence, 
        .... (1.3) 
i.e. 
λ = 2 dhkl sin θ  .....(1.4) 
 
 The Ewald circle represents (Fig. 22), in reciprocal space, all the possible 
points where planes (reflections) could satisfy the Bragg equation. In 3-dimension, a 
Ewald sphere represents all the possibilities. For simplicity, it is often drawn as a 
circle in two dimensions. 
 
2.6 PROTEIN CRYSTALLIZATION AND DATA COLLECTION 
Crystals can be interpreted as an infinite array in which unit-cells are arranged 
in the three-dimensional space according to well-defined symmetry. Growth of a 
single and well defined diffracting crystal forms the basic and essential prerequisite 
for X-ray crystallographic protein structure determination (Blow, 2002). Producing 
high quality crystals has always been the bottleneck in structure determination and it 
is still not understood why some proteins crystallize with ease while others stubbornly 
refuse to produce suitable crystals (Chayen, 2004). It requires a protein to be purified 
to homogeneity and concentrated to a supersaturated state to generate crystals.  
 Crystal growth has three steps: nucleation, growth and cessation of growth. 
However, identifying a successful crystallization condition for a new protein is like 
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looking for a needle in a haystack (McPherson, 2009). Also, truncation of a protein at 
the N or C terminus may lead to proper crystallization and diffraction. In addition, 
tagging a partially soluble or partially homogeneous protein with maltose binding 
protein (MBP) (Gruswitz et al., 2005) or lyzozyme (Cherezov et al., 2007) at the N or 
C terminus has given a positive effect in crystal formation (nucleation site for crystal 
formation) as well as in enhancing solubility. Different techniques are employed for 
setting up crystallization trials which include sitting drop vapor diffusion, hanging 
drop vapor diffusion, sandwich drop, batch, micro batch under oil, micro dialysis and 
free interface diffusion. While vapor diffusion has been very popular and successful 
for the past 40 years, microbatch, which is the simplest method, is a relatively new 
technique. 
 Sitting and hanging drop methods are easy to manipulate, require a small 
amount of sample, and allow large amount of flexibility during screening and 
optimization. Once a lead is obtained as to which conditions may be suitable for 
crystal growth, the conditions can generally be fine-tuned by making variations to the 
parameters including precipitant, pH, salt, temperature, etc. Cryo-preservation of good 
crystals is also a defining factor in protein crystallography. This is helpful in 
protecting a protein crystal from the naturally damaging effects of X-rays during data 
collection. Usually, glycerol, sucrose, propanediol, glycol, etc. are used for cryo-
preservation. No additional cryo protection agent is needed if a crystal is already 
grown in some natural cryo buffers or glutaraldehyde. 
 
2.7 X-RAY DIFFRACTION 
With the discovery of X-rays by Roentgen in 1895 and after its 
crystallographic application by von Laue in 1912, Bragg and Bragg established the 
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theory of X-ray diffraction, mainly as an outcome of interaction between 
electromagnetic radiation and electrons of atoms. 
 
2.7.1 X-ray sources 
X-rays are electromagnetic radiation with wavelength in the range 0.1-100 Å. 
They are produced when accelerated electrons are allowed to bombard a metal target 
in the presence of an electric field. This collision actually displaces an electron from a 
low energy orbital of the metal target. The displaced (and excited) electron returns 
back to its ground state by emitting its excess energy as X-rays at a wavelength 
characteristic to the corresponding shell. In general, Kα transition wavelengths are 
very strong and useful. Other associated radiation, like Kβ, are eliminated to produce 
monochromatic (single wavelength) X-rays. In practice, copper radiation is widely 
used for detection by film, which is more sensitive to Cu Kβ and molybdenum, which 
gives short wavelength X-rays, is more commonly used for scintillation counters 
detectors. 
 
2.7.2 Geometric data collection 
 X-rays, when passed through a crystal, are diffracted by electrons. Usually, the 
crystal is rotated through 180º or 360º, in steps of 1º (or 0.5º) oscillation and the 
resulting reflections are recorded using an image plate or charge coupled device 
(CCD) detector. Each reflection is the collective diffraction effect of all atoms in the 
crystal in a particular direction satisfying Bragg’s law. For structure determination, 
the intensities of as many reflections as possible must be measured. During data 
collection, two major effects are recorded. First is the geometry of diffraction which 
tells us the space group of the crystal. Second is the intensity of each diffracted 
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reciprocal lattice point, which is ultimately related to electron distribution in the unit-
cell. An X-ray diffraction measuring instrument consists of two parts, namely, the 
mechanical goniometer to rotate crystal and the detecting device to measure the 
intensities of diffracted beams (Fig. 23). The crystal can be rotated on three 
independent axes of rotation (ω, χ and φ) so that any reciprocal lattice point can be 
brought into diffraction position. Different detectors utilize different physical 
mechanisms to record X-ray reflections. The most popular systems include the 
photographic film, multiwire proportional chamber (MWPC), the solid state charge 
coupled device (CCD) and image plate (which records signal via color centers, 
followed by a laser scan). 
 
 
Figure 23. The four-circle diffractometer. Figure adapted from SERC lecture 
notes. 
 
2.8 DATA REDUCTION 
A diffraction reflection provides us the reciprocal lattice position in a unit-cell, 
through its index triple (hkl), and its intensity. The structure amplitude of a reflection, 
|Fhkl| (see Sec 2.10), is derived as the square root of the measured intensity, in data 
reduction; the Miller indices and structure amplitude of all reflections are derived. 
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The reflections are scaled and all systematic errors, such as absorption (arising from 
non irregular crystal shape), non-linearity in the monitoring of the incident beam 
intensity by the detector, and changes in the average diffracted intensities due to 
variation in the total diffracting volume of the crystal sample arising when part of the 
crystal moves in or out of the incident beam, are corrected. Also, data are to be 
corrected for the thermal motion of atoms (which causes the fall-off of intensity with 
increased scattering angle) and radiation damage which contributes to reduction in the 
intensity as a function of resolution (Ravelli and Garman, 2006). In practice, multiple 
observations of symmetry related reflections (either from different crystals or from 
the same crystal) are merged to give only the unique reflections for that particular 
crystal system. The quality of merged data is verified by Rsym, Eq. 1.5, with typical 
values of less than 3% for low resolution data and upto 20% for data near the high 
diffraction resolution limit (Diederichs and Karplus, 1997). 
Rsym = ΣhklΣi[|Ii(hkl) – <I(hkl)>| / ΣhklΣi Ii(hkl)]…. (1.5) 
 Different data reduction practices have been recommended. Cowtan (1996) 
has shown how missing reflections affect the reproduction of an image from 
diffraction data (Cowtan and Main, 1996). The completeness of low resolution data is 
important in the placement of missing parts of a structure, while refinement may 
benefit from the inclusion of high resolution data even if the merging R is up to 40% 
(Dodson et al., 1996). Depending on the structure determination method, the Bijvoet 
pairs of a reflection can either be treated separately to give h,k,l,F+,F- (acentric) or 




2.9 WAVES. FOURIER SYNTHESIS AND FOURIER TRANSFORM  
The Fourier transform, after the French mathematician Joseph Fourier, 
describes the mathematical relationship between two related entities, for example, 
electron distribution in a crystal and the diffraction effect. Fourier demonstrated that 
for any function f(x), there exists another Function F(h) such that  
                    
  
  
 …. (1.6) 
 Where F(h) is called the Fourier transformation (FT) of f(x), and the unit of the 
variable h is the reciprocal of the unit of x. The Fourier transform operation is 
reversible. That is, the same mathematical operation that gives F(h) from f(x) can be 
carried out in the opposite direction to give f(x) from F(h), as x and h are reciprocal to 
each other. 
                     
  
  
 …. (1.7) 
 The above functions f(x) and F(h) are one-dimensional. If stated in three 
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2.10 ELECTRON DENSITY AS FOURIER SERIES 
The unit-cell can be represented as an assembly of electron density in several 
defined volume elements. The electron density of each volume element, centered at a 
point (xyz), is roughly the average value of  (xyz) in that region. Smaller the volume 
elements, the more precisely these averages approach the correct value of  (xyz) at all 
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  …. (1.11) 
 
2.11 THE PHASE PROBLEM 
In order to compute Eq. 1.11, we need to know Fhkl. In other words, this 
structure factor can be split into two terms: measurable structure amplitude and 
immeasurable phase. An electron density map represents a function of the known 
amplitude [(I)
1/2] and the unknown phases α'hkl. In fact, the phase angle of a reflection 
is the relative angular difference between the resultant diffraction wave and the 
incident wave at the origin of the unit-cell. This angular information is very important 
in the calculation of Eq. 1.11. Determination or estimation of this unknown phase 
angle for each reflection is known as the phase problem in X-ray crystallography. 
Several methods are employed to solve this problem which usually gave an initial set 




2.11.1 Patterson function  
The use of the Patterson function was originally proposed by Arthur Lindo 
Patterson in 1935, primarily to solve the phase problem. He pointed out that Fourier 
calculation can be performed by using the phaseless quantity |F|
2
 as coefficients. He 
showed that whereas the usual synthesis with F's as coefficients showed the 
distribution of atoms in the cell, the map calculated with |F|
2
 gave peaks 
corresponding to interatomic vectors. Thus a peak at a point uvw in a Patterson map 
indicates that two atoms exist in the crystal at x1, y1, z1 and x2, y2, z2, such that u = x1- 





   ….. (1.12) 
 For a molecule containing N atoms in a unit-cell, the Patterson synthesis will 
show N
2
 peaks, corresponding to the N possible vectors that can be drawn from each 
of the N atoms. It is basically a Fourier transform of intensities rather than structure 
factors. Vector peaks in the corresponding Patterson map are limited to only 24 space 
groups. This simplification reflects the loss of information suffered when proceeding 




2.11.2 Isomorphous replacement 
In this method, a crystal is soaked in a heavy atom solution or a protein is co-
crystallized with a heavy atom. The addition of the heavy atom should not affect 
crystal formation, protein conformation or unit-cell dimensions, in comparison to its 
native form. In other words, the native and the derivative crystals should be truly 
isomorphic (Taylor, 2003).  
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 Data sets from native and heavy-atom derivative crystals are collected. 
Interpretation of difference Patterson maps will reveal the locations of heavy atoms in 
the unit-cell, from which the phases of reflections can be computed. Since the 
structure factor of the heavy atom derivative (Fph) is the vector sum of the lone heavy 
atom (Fh) and the native crystal (Fp), the phase of the native Fp can be solved 
geometrically from the equation, 
Fph = Fp + Fh .… (1.13)  
 
2.11.3 Direct Methods 
This method is primarily used for phase determination in small molecule 
crystallography. Direct methods depend upon the existence of a mathematical 
relationship among certain combination of phases. These relationships will establish 
initial phase estimates, which upon converging yield a complete set of phase 
(Hauptman, 1997; Uson and Sheldrick, 1999). The major limitation of this method is 
a need of very high resolution data, mostly around 1 Å. 
   
2.11.4 Anamolous dispersion 
Another method of obtaining phases from heavy atom derivatives is by using 
the property that selected heavy atoms absorb X-rays at specific wavelengths. Due to 
this absorption, Friedal’s law does not hold, resulting in unequal intensities for hkl 
and -h-k-l reflections. This condition produces anomalous scattering or dispersion. 
Usually sulphur and selenium in protein crystals are used as anomalous scatterers. 
The natural presence of sulphur in methionine and cysteine usually become helpful. 
Otherwise, the amino acid methionine can be substituted with selenomethionine by 
using selective media during protein expression. Multiwavelength anomalous 
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dispersion (MAD) data are collected usually at three wavelengths that correspond to 
‘peak’, ‘inflection’ and ‘remote’ points, using a synchrotron (Guss et al., 1988). 
 
2.11.5 Molecular replacement 
Molecular replacement is another method in which a previously solved 
homologous protein structure can be used to derive the initial phases for the crystal in 
hand. A Patterson map of the crystal is created and correlated with a second Patterson 
map from the homologous model until an acceptable set of phases is derived. 
 The main limitation of this process is the availability of a known structure 
with high sequence and structure homology. As a rule of thumb, molecular 
replacement with modern programs will probably be fairly straightforward if the 
model is fairly complete and shares at least 30% sequence identity with the unknown 
structure. The main steps in the modern program PHASER (McCoy et al., 2007) are:  
Likelihood: On the basis of probability, ‘likelihood’ measures the agreement of the 
model with data. In molecular replacement, the "model" being tested includes not 
only the structure of the template, but also the orientation and/or position of that 
template in the unit-cell of the target, as well as parameters describing the sizes of 
different sources of error. In other applications (such as structure refinement), the 
effect of model errors on the ability to predict the diffraction data can be determined 
by comparing the observed and calculated structure factor amplitudes. In molecular 
replacement, the structure factor comparison cannot be undertaken until after the 
molecular replacement problem is solved, so the impact of errors has to be estimated 
before the molecular replacement calculation.  
Ensembles. In molecular replacement, a protein model is treated as a rigid body and is 
rotated and translated to place in the target unit-cell. The components of a model are 
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often whole proteins or even whole complexes, but for flexible proteins they may be 
smaller pieces such as domains or sub-domains. In Phaser, these components are 
treated as a rigid body and termed as ensemble. For each ensemble, Phaser computes 
a set of statistically-weighted average structure factors (weighted according to 
expected error, and taking account of correlations between pairs of models), which is 
used in molecular replacement calculations.  
Fast rotation function. In Phaser, cell content analysis during molecular replacement 
involves two steps: rotation and translation. In the rotation function, the Patterson map 
of the unknown structure is compared to Patterson maps derived from the known 
homologous structure in different orientations. Historically, R-factors and/or 
correlation coefficients were used to score the rotation function. However, modern 
programs use maximum likelihood-based algorithms. The highest correlations (and 
therefore scores) are obtained when the two structures (known and unknown) are in 
similar orientation(s), which are output in Euler angles or spherical polar angles. In 
Phaser, after rotational function, a cluster analysis is carried out to find unique peaks. 
 By default, only orientations with log-likelihood values that are above 75% of 
the mean are reported. Two scores are given for each orientation: the log-likelihood-
gain (LLG) and the Z-score. Usually, a Z score between 6 and 8 is considered as a 
reliable value for the validation of an identified solution, which will be used further 
for refinement and map improvement.  
Fast translation function. In the translation function, the now correctly oriented 
known model can be correctly positioned by translating it to the correct co-ordinates 
within the asymmetric unit. This is accomplished by moving the model, calculating a 
new Patterson map, and comparing it to the Patterson map of the unknown structure. 
This brute-force search is computationally expensive and fast translation functions are 
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now more commonly used. The positions with high correlation values are output 
(Rossmann, 1990). 
 
2.12 MODEL BUILDING AND REFINEMENT 
The outcome of the anomalous dispersion, isomorphous replacement and 
molecular replacement techniques, can give an initial set of phase values, in the form 
of an initial model. This initial model must be fit realistically with an electron density 
map that is computed having components of the collected diffraction data and the 
present model. This involves cycles of model building and refinement. During model 
building, the geometrical quality of the model is improved, based on amino acid 
properties, stereochemistry, geometrical constraints of peptide bonds, dihedral angles 
of the main chain etc. Relatively, side chains are less restricted than the main chain. 
Side chains have preferred rotomer positions, which need to be fixed during the initial 
steps of model building. This whole process leads to stable secondary structures (α-
helices and β-strands), which help further to construct loops that connect these 
secondary structures. Helices become visible even in 5.5 Å resolution maps while β-
strands tend to break up at resolution less than 3.0Å. Using the fitted model, new 
phase are calculated. If the model is correct, the subsequently calculated map with the 
new phases will show additional features, leading to further improvement of the 
model while a wrong model will degrade the map. Iteratively, we follow the good 
sections of the map and add more protein segments to complete the model (McRee, 




2.12.1 Least-squares methods 
The refinement process consists of a version of least-squares fitting. In a 
simple least-squares method, the aim is to find a function y = f(x) that fits a series of 
observations (x1, y1), (x2, y2).....(xi, yi). The solution to the problem is a function f(x) 
for which the sum of the squares of distances between the data points and the 






 That is, f(x) is the function that minimizes D, the sum of the squared difference 
between observed (yi) and calculated f(xi) values. The differences are squared to make 
them all positive and prevent a large number of random difference add up to drive D 
toward 0. An optional weighting factor, wI, reflects the reliability of the observation. 
Normally in statistics, the weighting factor is the deviation computed from multiple 
measurements of the same data point (xi, yi). 
 
2.12.2 Molecular dynamics refinement 
This approach treats the model as if its energy decreases when its fit to the 
native crystallographic data improves. In refinement by simulated annealing, the 
model is allowed to move to a high temperature and lifted out of local energy minima. 
Then, the model is cooled slowly to find its preferred conformation at the temperature 
of diffraction data. Throughout the process, the computer is searching for the 
conformation of the lowest energy with the assigned energy is partially dependent on 
an agreement with diffraction data. 
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2.12.3 Additional parameters for refinement 
Besides the atomic positions that are included in refinement, other parameters 
are included as well. One is the temperature factor Bj of an atom j, a measure of how 
much the atom oscillates around the position specified in the model. As atoms are not 
static in the model, they always vibrate around their positions, especially atoms at side 
chains and the termini. Diffraction is affected by this variation in atomic positions, so 
it is realistic to assign a temperature factor to each atom. Another parameter included 
in refinement is the occupancy nj of each atom j, a measure of the fraction of the atom 
j that actually occupies the position specified in the model. For example, if two 
conformations, especially in selected side chains, occur with equal frequencies, then 
the involved atoms receive occupancies of 0.5 each for their two possible positions. 
By including occupancies in refinement, estimates of the frequency of alternative 
conformations is obtained, which gives some information about the dynamics of the 
protein model. 
 A least-squares procedure will find the minimum that is nearest the starting 
point. So it is important that the starting model parameters are near the global 
minimum. Otherwise, the refinement will converge into an incorrect local minimum, 
from which it cannot extract itself. The greatest distance from the global minimum 
from which refinement will converge properly is called the radius of convergence. 
Additional constraints and restrains used in the refinement computation will increase 
the radius of convergence and thus increase the probability of finding the global 
minimum. A constraint is a fixed value for certain parameter. We may constrain all 
occupancies to a value to 1.0. A restraint is a subsidiary condition imposed on the 
parameters, such as the condition that all bond lengths and bond angles are within a 
specified range of values. With the help of modern computers, least-squares restraints, 
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including bond length, bond angle and conformational energies and energies of 
noncovalent interactions are added to the overall energy refinement to find the 
structure of the lowest energy. 
 Translation libation screw (TLS) refinement in Refmac can be used in 
improving the refinement behaviour by accounting for anisotropy in the data and, and 
in case of non-crystallographic symmetry (NCS), it accounts for overall differences in 
displacements between molecules. TLS parameters are refined assuming the physical 
model of a rigid body, i.e. that all atoms in the TLS groups have amplitudes (in 3 
dimensions) appropriate to a rigid body and that all atoms move in phase. However, if 
for example one constructs a model in which all atoms in the TLS group have rigid 
body amplitudes but with one half moving in anti-phase with the other half, one 
would get the same derived U values and hence the same fit to the observed structure 
factors (Winn et al., 2001). 
 
2.13 IMPROVEMENT IN MAP 
Improvement of an electron density map involves continuous model building 
and refinement procedures .The major steps that help for this improvement are as 
follows: 
 
2.13.1 Solvent flattening 
It is a way of improving the experimentally calculated phases. In general, an 
initial electron density map, calculated from measured reflection data and calculated 
phases, is not much clear. The process that assigns the regions of a protein molecules 
a high value of  (x,y,z) and a low value of   for all surrounding areas of bulk solvent 
is called solvent flattening. At each point, the value of  (x,y,z) in the Fobs map is 
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evaluated. Simply it reduces the noise level when at least the backbone of the protein 
molecule is bit clear. All density outside the backbone boundary is set to zero or some 
low values and the new density distribution is back transformed to give a new phase 
set. The combination of this new phase set and the starting set actually give an 
improved phase set. This literary process needs a lot of repetition to achieve the best 
phase set (Wang, 1985). 
 
2.13.2 Extension of phases 
Phase extension is another process in which a known and reasonable number 
of phases (e.g. from an initial structure model) can be extended to a higher resolution 
data set. The process involves a gradual increase in the number of terms in the Fourier 
series by adding native intensities of higher resolution than the current model. This 
work must be performed gradually and judiciously to avoid introducing any bias. In 
this manner, the phases of low resolution reflections are improved and phases are 
extended to higher resolution reflections, simultaneously. 
 
2.13.3 Non crystallographic symmetry averaging 
This process is important when the asymmetric unit contains more than one 
molecule, that is, symmetrically related locally, rather than using any crystallographic 
symmetry operation. For example, the biological unit of a protein may be a 
homodimer and the protein may crystallize in the space group P1, with a dimer in the 
unit-cell. This means, the two monomers are related to each other with local twofold 
rotation symmetry, known as non crystallographic symmetry (NCS). It is not unusual 
that one monomer may have well defined density in its region that is poorly defined in 
the other monomer and vice versa. It will be structurally advantageous to average the 
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density of the two molecules so that the average density will be equally defined in 
both molecules. In order to perform this density modification using NCS averaging, 
two masks that define the independent monomers and the operator that relate the 
masks are first derived. Care should be taken to avoid overlap between masks if 
several masks (e.g. for different domains for a monomer) are used. Since NCS 
averaging is mostly performed in conjunction with other density modification steps 
(e.g. solvent flattening), the NCS masks are valid within the protein region only and 
should not contain too much of the solvent region. 
 
2.14 FINAL STRUCTURE 
After several rounds of refinement and map fitting, the model is slowly 
converged to the final model. The progress of iterative real and reciprocal space 
refinement is monitored by computing the difference between the measured structure 
factors |Fo| and calculated structure factors |Fc| from the current model. When the 
model converges to a correct model, this difference, defined as the residual factor, 










R .... (1.14) 
 A desirable target R factor for a protein model should be less than 0.3 (Morris 
et al., 1992). Occasionally, small and well ordered protein structures may refine to an 
R of about 0.1. R-free is another monitoring parameter calculated in the same way as 
R factor using a small subset usually 5% of total reflection that has not been used in 
the structural refinement (Brunger, 1992). In addition to monitoring the R factor as a 
convergence indicator, it is important to make sure that the model is chemically, 
stereochemically and conformationally reasonable. The geometrical integrity is 
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normally checked with programs like PROCHECK (Laskowski, et al. 1993) and 
Molprobity (Davis et al., 2007). In a well refined model, the root mean square (RMS) 
deviation of bond lengths should be no be more than 0.02 Å and that of bond angles is 
less than 2°, with respect to ideal values (Engh and Huber 2006). 
 
2.15 DEPOSITION OF PROTEIN STRUCTURE  
The final structure will be having acceptable statistics of all refinement 
parameters. After that the protein structure is ready for submission in the Protein Data 
Bank, a crystallographic database with organizational similarity to Cambridge 
Structure Database (for small molecules) and Inorganic Chemical Structure Database 
(for inorganic compounds). These databases are open sources and structure 
coordinates are available to public for further use. 
 A crystallographic project, in the modern time, requires the use of several 
computer programs. The details of some of the contemporary computer programs are 
provided in Table 3. 
 
Table 3. Commonly used computer programs in protein crystal structure 
determination. 
 
Program Website Function 
MOSFLM www.mrc-
lmb.cam.ac.uk/harry/mosflm  
Data image processing, 
integration, reduction 
and scaling via CCP4. 




CCP4 program www.ccp4.ac.uk  Data collection, data 
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Suite processing, phasing, 
ML refinement, model 
building, validation. 
XPLOR/CNS cns.csb.yale.edu  Program pioneering SA 
and MD in refinement 
of X-ray and NMR 
data. Complete package 
including phasing and 
MR 
SOLVE/RESOLVE www.solve.lanl.gov  Combined ML HA 
solution, phasing, 
reciprocal space density 






www.globalphasing.com  ML HA refinement, 
excellent phasing, 
density medication. 
Interfaces with CCP4 
ARP/wARP 
warpNtrace 
www.embl-hamburg.de/ARP  Map improvement via 
dummy atom 
refinement and model 
building. Works best at 
higher resolution 
BnP www.hwi.buffalo.edu./SnB  Direct methods full 




PHASER2.1 www.ccp4.ac.uk/html/phaser  MR based on likelihood 
and ensembles submitted 
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Coot www.ysbl.york.ac.uk/~lohkamp/coot  Advanced graphic 
modeling program still 
under development 
Pymol1.3 www.pymol.org/  Molecular models 
visualization program 
 
Notes: HA: Heavy atom; ML: maximum likelihood; MD: molecular dynamics; 




The main objectives of this project is as follows, 
1. To identify drug-like molecules specific for MMP-13 hemopexin (Hpx) 
domain. 
2. To validate these drug-like molecules in vitro studies 











CHAPTER 3. MATERIALS AND METHODS 
 
3.1 SEQUENCE-BASED ANALYSIS TO IDENTIFY CHARACTERISTIC 
 FUNCTIONAL RESIDUES OF THE HPX DOMAIN OF MMP-13 
The identity of characteristic residues specific to the Hpx domain of MMP-13 
has not been reported previously (Lauer-Fields et al., 2009). We conducted a 
sequence based analysis to identify these amino acid residues by performing multiple 
sequence alignment and using the AVANA tool 
(http://sourceforge.net/projects/avana/) (Miotto et al., 2008), which allows 
comparison of alignments using mutual information to identify characteristic sites. 
The sequences of all reported human MMP proteins were extracted by 
performing PSI-BLAST (McGinnis and Madden, 2004) against the non-redundant 
(nr) protein database using the query sequence of MMP-13, which was obtained from 
the Protein Data Bank (Berman et al., 2000) (PDB ID:1PEX). A total of 50 MMP 
sequences were obtained from the BLAST search. These sequences were then 
multiple sequence aligned using Muscle v3.6 (Edgar, 2004), and the resulting 
alignment was manually inspected and corrected for misalignments using BioEdit 
(Hall, 1999) and represented using ESPript 2.2(Gouet et al., 1999). The regions of the 
alignment representing the pro-peptide domain, catalytic domain and the linker region 
were deleted, leaving only the Hpx domain. 
The alignment file of only the MMP Hpx domain sequences was then 
submitted to AVANA to identify residues that are completely (100%) conserved and 
characteristic to MMP-13 (i.e. unique to sequences of MMP-13 only). AVANA has a 
built-in functionality to identify characteristic sites between subsets of sequences in 
an alignment using entropy and mutual information theories (Miotto et al., 2008). 
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Herein, the two subsets for our alignment in AVANA were (i) 8 MMP-13 sequences 
and (ii) all other MMPs (42 of them). Having identified the Hpx characteristic 
residues (abbreviated as HCR) of MMP-13 (i.e. HCR-13), those that matched the 
putative functional residues of MMP-13 Hpx domain (Gomis-Ruth et al., 1996), 
HCR-13pf were also identified. Two main caveats herein include the small sample size 
and the sampling bias for the MMP sequences reported in the public database NCBI. 
However, the data used in this study was the most representative and comprehensive 
available in the public database to date (as in May 2009). Furthermore, the 
characteristic residue list can be refined with the availability of more sequence data in 
the future. 
 
3.1.1 Virtual screening 
We next aimed to identify and characterize ligands interacting with the HCR-
13pf. The in silico structure-based high-throughput virtual screening (HTVS) method 
of Glide, version 5.5 (Schrödinger, LLC, New York, 2009) (Friesner et al., 2004), was 
used to identify potential ligand molecules that interacted with at least one of the 
HCR-13pf residues on the 3D structure of MMP-13 (PDB ID: 1PEX). The binding of 
ligands to these residues is postulated to render selectivity to the inhibition of the 
proteolytic activity of the enzyme MMP-13. A total of 16,908 molecules derived from 
public databases namely Maybridge (14,400; www.maybridge.com), PubChem 
(Wang et al., 2009) (2438; obtained from Shanghai Institute of Organic Chemistry) 
and Binding (70; www.bindingdb.org), were selected for virtual screening against 
1PEX. 
Before performing HTVS, hydrogen atoms and charges were added to the 
crystal structure of 1PEX and then the complex was submitted to a series of 
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restrained, partial minimizations using the optimized potentials for liquid simulations 
all-atom (OPLS-AA) force field (Jorgensen et al., 1996). The 3D structure was 
processed by use of the ‘protein preparation module’ with the ‘preparation and 
refinement’ option before docking. The grid-enclosing box was centred to all HCR-13 
residues in 1PEX, so as to enclose the residues within 3 Å from their centroid. A 
scaling factor of 1.0 was set to van der Waals (VDW) radii for these residue atoms, 
with the partial atomic charge less than 0.25. The ligand molecules collected from the 
databases were prepared using ‘LigPrep’ module and were subsequently subjected to 
Glide ‘Ligand docking’ protocol with HTVS mode. 
 
3.1.2 Glide extra precision docking for the screened ligands 
All the ligands selected from the screening step were then subjected to Glide 
docking with extra precision (XP) to identify residues involved in hydrogen bond 
interactions with 1PEX. The Glide XP mode determines all reasonable conformations 
for each low-energy conformer in the designated binding site. In the process, the 
torsional degrees of each ligand are relaxed; even though the protein conformation is 
fixed. During the docking process, the Glide scoring function (G-score) was used to 
select the best conformation for each ligand. Final G-scores were analyzed based on 
the conformation at which the identified ligands formed hydrogen bonds to at least 
one of the HCR-13pf with optimal binding affinity. The docking procedures were 
performed on a Dell RHEL 5.0 workstation. 
 The ligands were then assessed for cross-reactive binding to MMP-1 and -8, 
using Glide XP; these MMPs were analyzed because they also contribute to 
collagenolytic activity and contain an Hpx domain as MMP-13. The better resolution 
3D structures for MMP-1 (PDB ID 1SU3, containing catalytic and Hpx domains) and 
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-8 (1BZS, only the catalytic domain) obtained from the PDB were used for docking. 
The binding analysis on these structures was focused on the known active site 
residues of the catalytic domain of MMP-1 (Jozic et al., 2005) and -8 (Matter et al., 
1999) and the reported putative functional residues of MMP-13 Hpx domain (residues 
285–295, Asp-Ala-Ile-Thr-Thr-Ile-Arg-Gly-Glu-Val-Met) (Lauer-Fields et al., 2009). 
It is noted that when aligned, the positions of the reported putative functional residues 
of the Hpx domain of MMP-1 do not correspond to those reported for MMP-13. This 
may be because of the selectivity of these two MMPs to different substrates, such as 
type I collagen for MMP-1 and type II for MMP-13 (Chung et al., 2004). 
 
3.1.3 Assessment of drug-like properties of selected optimized ligands 
The selected and optimized lead molecules from the cross-reactivity assay 
were studied for their drug-like properties based on Lipinski’s rule of five (Lipinski et 
al., 2001), by use of the ADME-Tox application at the Mobyle portal 
(http://mobyle.rpbs.univ-paris-diderot.fr). The percentage of their human oral 
absorption was also predicted to determine the toxicity levels, by use of QikProp 
version 3.2, Schrödinger, LLC, New York, NY, 2009 (Jorgensen, 2006). 
 
3.2 MOLECULAR AND STRUCTURAL METHODS 
Furthermore, based on the computational data, crystallization trials were 
carried out to determine the complex structure of the Hpx domain with the lead 
compounds. This is to validate whether the lead molecules bind to the expected 
characteristic and functional residues that have been identified using cheminformatics. 
Crystallization trials were also carried out to obtain the structure of full length MMP-
13 (collagenase-3). Constructs expressing the Hpx domain alone and full length 
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MMP-13 were prepared. The proteins were expressed in E. coli BL21 cells and finally 
crystallization trials were performed. 
 
3.2.1 Expression and purification of Hpx domain of MMP-13 
 The Hpx was cloned into PET-M vector with the addition of N-terminal non-
cleavable (His)6 tag. The constructs were co-transformed into the strain BL21 (DE3) 
E. coli for protein expression. The E. coli were cultured in 10 litres of LB medium at 
37°C until the A600 nm reached 0.5-0.6. The culture was induced with 0.3mM IPTG 
and continued to grow at 16°C overnight. Cells were harvested by centrifugation 
(8000 rpm, 20 min, 4°C), and the pellet was resuspended in the 40 ml of lysis buffer 
containing 50 mM Tris HCl PH 7.2, 150 mM NaCl, 6 M GnHCl, 5 mM CaCl2 and 1 
protease inhibitor tablet (Roche).  
 After sonication the cell lysate was centrifuged at 17000 rpm for 30 min at 
4°C (JA-25.50 fixed angle rotor, Beckman Coulter centrifuge). The pellet, containing 
inclusion bodies from the over expression of Hpx, was resuspended in 25 ml of 
denaturation buffer containing 50 mM Tris HCl PH 7.2, 150 mM NaCl, 6 M GnHCl 
and 5 mM CaCl2, vortexed till the pellet got re-suspended in the buffer and then 
centrifuged at 17000 rpm for 30 min at 4°C (JA-25.50 fixed angle rotor, Beckman 
Coulter centrifuge) (Pathak et al., 1998). 
 The supernatant was allowed to bind to the nickel NTA resin for an hour at 
room temperature (22°C) and was subsequently washed twice with wash buffer 50 
mM Tris HCl pH 7.2, 150 mM NaCl, 6 M GnHCl and 5 mM CaCl2. Finally the 
protein was eluted in two steps using the elution buffer (500 mM imidazole pH 7.2). 
The eluted protein was refolded using rapid dilution with refolding buffer 50 mM Tris 
HCl pH 7.2, 150 mM NaCl, 1 M GnHCl, 5 mM CaCl2 to remove GnHCl (Muta et al., 
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2010). The refolded protein was then loaded onto a size exclusion column (Superdex 
75, GE Healthcare) equilibrated with the buffer containing (50 mM Tris HCl pH 7.2, 
150 mM NaCl, 5 mM CaCl2 and 5% glycerol. The eluted Hpx protein was 
concentrated up to 2 mg/ml with the use of 3K Amicon Ultra-15 Centrifugal Filter 
Units (Millipore). 
 
3.2.2 MALDI-TOF MS and MS-MS Analysis of Hpx of MMP-13 
 Molecular weight determination was done with the aid of a Voyager STR 
MALDI-TOF mass spectrometer (Applied Biosystems). For MS/MS analysis, sample 
digestion, desalting and concentration steps were carried out by using the Montage® 
In-Gel digestion Kits (Millipore Corp.) Protein spots were analyzed using an Applied 
Biosystems 4700 Proteomics Analyzer MALDI-TOF/TOF (Applied Biosystems, 
Framigham, MA, USA). Data processing and interpretation was carried out using the 
GPS explorer Software (Applied Biosystems) and database searching was done using 
the MASCOT program (Matrix Science Ltd., London, UK). The NCBI database was 
used for combined MS and MS/MS search. [Samples for the mass spectrometry 
experiments were prepared and analyzed from PPC, DBS-NUS facility]. 
 
3.2.3 Crystallization and data collection 
 Crystallization trials were carried for the purified full length and Hpx protein 
out at room temperature by hanging-drop vapor-diffusion method using crystallization 
screens from Hampton Research (Aliso Viejo, CA, USA) and Jena Bioscience screens 




3.2.4 Expression and purification of full length MMP-13 
 The full length was cloned into PET-32a vector with the addition of N-
terminal non-cleavable (His)6 tag. The constructs were co-transformed into the strain 
BL21 (DE3) E. coli for protein expression. The E. coli were cultured in 10 litres of 
LB medium at 37°C until the A600 nm reached 0.5-0.6.  The culture was induced 
with 0.4 mM IPTG and continued to grow at 16°C overnight. Cells were harvested by 
centrifugation (8000 rpm, 20 min, 4°C), and the pellet was resuspended in the 40 ml 
of lysis buffer containing 50 mM Tris HCl pH 7.5, 150 mM NaCl, 6 M GnHCl, 1 mM 
ZnCl and 1 protease inhibitor tablet (Roche).  
 After sonication the cell lysate was centrifuged at 17000 rpm for 30 min at 
4°C (JA-25.50 fixed angle rotor, Beckman Coulter centrifuge). The pellet, containing 
inclusion bodies from the overexpression of Hpx, was resuspended in 25 ml of 
denaturation buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM ZnCl and 6 M GnHCl 
and vortexed till the pellet got re-suspended in the buffer and then centrifuged at 
17000 rpm for 30 min at 4°C (JA-25.50 fixed angle rotor, Beckman Coulter 
centrifuge) (Pathak et al., 1998). 
 The supernatant was allowed to bind to the nickel NTA resin for an hour at 
room temperature (22°C) and was subsequently washed twice with wash buffer (50 
mM Tris HCl pH 7.5, 150 mM NaCl, 6 M GnHCl and 1 mM ZnCl. Finally the protein 
was eluted in two steps using the elution buffer (500mM imidazole pH 7.2). The 
eluted protein was refolded using rapid dilution with refolding buffer (50 mM Tris 
HCl pH 7.5, 150 mM NaCl, 1 M GnHCl and 1 mM ZnCl  to remove GnHCl (Muta et 
al., 2010). The refolded protein was then loaded onto a size exclusion column 
(Superdex 200, GE Healthcare) equilibrated with the buffer containing (50 mM Tris 
HCl pH 7.5, 150 mM NaCl, 1 mM ZnCl and 5% glycerol. The eluted Hpx protein was 
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concentrated up to 2 mg/ml with the use of 30K Amicon Ultra-15 Centrifugal Filter 
Units (Millipore). 
 
3.2.5 MALDI-TOF MS and MS-MS analysis of full length 
 Molecular weight determination was done with the aid of a Voyager STR 
MALDI-TOF mass spectrometer (Applied Biosystems). For MS/MS analysis, sample 
digestion, desalting and concentration steps were carried out by using the Montage® 
In-Gel digestion Kits (Millipore Corp.) Protein spots were analyzed using an Applied 
Biosystems 4700 Proteomics Analyzer MALDI-TOF/TOF (Applied Biosystems, 
Framigham, MA, USA). Data processing and interpretation was carried out using the 
GPS explorer Software (Applied Biosystems) and database searching was done using 
the MASCOT program (Matrix Science Ltd., London, UK). The NCBI database was 
used for combined MS and MS/MS search. [Samples for the mass spectrometry 
experiments were prepared and analyzed by the PPC, DBS-NUS facility]. 
 
3.2.6 Crystallization and data collection 
 Crystallization trials were carried for the purified full length and Hpx protein 
out at room temperature by hanging-drop vapor-diffusion method using crystallization 
screens from Hampton Research (Aliso Viejo, CA, USA) and Jena Bioscience screens 
(Jena, Germany).   
 
3.3 IN VITRO AND IN VIVO METHODS 
3.3.1 Basal level expression of MMP-13 of breast and colon cancer cell lines 
MMP-13, which is a specific target for arthritis and cancer, was found to be 
higly expressed in breast and colon cancer (Delassus et al., 2011; Yamada et al., 
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2010). We validated the basal level expression of MMP-13 in various breast (MDA-
MB-231, BT-549 and MCF-7) and colon (HT-29, HCT-116, SW-620 and SW-480) 
cancer cell lines using western blot. 
All cells were grown until they reached 80% confluence. At the time of 
harvesting, cell pellets were collected and completely lyzed with RIPA lysis buffer 
(50 mM Tris at pH 7.5, 150 mM NaCl, 1% v/v NP-40, 1% v/v deoxycholic acid, 0.1% 
v/v SDS and 1 mM EDTA) containing 1 mM PMSF, leupeptin, pepstatin A and 
aprotinin before subjected to SDS-PAGE. Based on the bovine serum albumin (BSA) 
standard 40 µg of protein was loaded into each well and the set up was run at 120 
volts for 1 hr 10 min. The resolved proteins were then transferred onto nitrocellulose 
transfer membrane, blocked with 5% milk and incubated with specific primary 
antibodies at 4°C overnight, followed by secondary antibodies before visualizing on 
X-ray films using enhanced chemiluminescence (Pierce). Following transfer and 
blocking, the membrane was thoroughly washed with Tris buffered saline for 3 times, 
each for 5 mins and then probed with diluted (1:1000) polyclonal rabbit anti human 
MMP-13 primary antibody (SC-30073-Santa Cruz Biotechnology, CA, USA) and left 
for about 12-16 hr shaking at 4°C. The membrane was washed thoroughly with Tris 
buffered saline for 5 times each for 10-15 min. The proteins were visualized using 
horseradish peroxidise-linked secondary antibodies and enhanced chemiluminescence 
(GE Healthcare).  
 
3.3.2 Cell viability assay 
The study of cell viability and proliferation is very important for evaluating a 
cell population’s responses to external factors, such as growth factors, antibiotics and 
anti-cancer drugs. The MTT cell viability and proliferation assay allows simple, 
77 
 
accurate and reliable counting of metabolically active cells, based on the conversion 
of pale yellow tetrazolium MTT [(3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] to purple formazan crystals. The crystals can be 
solubilised and then spectrophotometrically quantified. 
MDA-MB-231 cells (3x103) cells were serially diluted and are plated into 96-
well plate with 100 µL of fresh RPMI media in each well. After 24 hr the media was 
removed and replaced with serum free media and then the cells were treated with six 
drug compounds and left for 48 and 72 hr with concentrations ranging from 0, 25, 50 
and 100 µM respectively. Twenty micro litres of MTT solution (5mg/mL in 
phosphate buffered saline [PBS]) was added to each well and incubated for four hours 
at 37°C. A negative control of 20 µL of MTT solution was added to 100 µL of 
medium alone. After aspiration of the supernatant, 150 µL of DMSO were added to 
each well. The plate was shaken for 10 min. Absorbance at 490 nm was measured 
with an ELISA reader (Bio-Rad, Hercules, CA, USA).  
 
3.3.3 Heparin-enhanced zymographic detection of MMP-13  
 MDA-MB-231 cells (6x105 cells) were treated with 100μM of compound 5, 
compound 6 and WAY-170523 (known inhibitor of MMP-13) of MMP-13 for 48 hr 
in a T75 culture flask. The resulting culture supernatant was concentrated using 
Amicon Ultra-15 Centrifugal Filter Units (Millipore Corporation, Billerica, MA, 
USA). Samples were treated with sample buffer without dithiothreitol and incubated 
at 55°C for 5 minutes. Equal volumes of samples were run on a 10% acrlamide gel 
containing 1 mg/ml gelatin at constant voltage (150 V). Ten microlitres of heparin 
(0.3 mg/ml in 1x sample buffer without SDS) was added to the lanes (to enhanced 
MMP-13 activity) for 30–40 min so that, after electrophoresis has began the heparin 
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would form a “box” or broad band with a molecular weight ranging between 40 and 
60 kDa (Yu and Woessner, 2001). Each gel was washed 2 times with 2.5% Triton X-
100, 50 mM Tris, pH 7.5, 4°C, 20 min each, to remove SDS and then 2 times with 
buffer plus 5 mM CaCl2.The gel was washed 3 times with incubation buffer (50 mM 
Tris, pH 7.5, 5 mM CaCl2) and then incubated in this buffer for 18 hr, 37°C, with 
gentle shaking. Gels were stained with 0.1% Coomassie blue in 40% MeOH, 10% 
acetic acid, for 45 min, and destained with 7% acetic acid. The gels were scanned and 
digitalized with a BioRad GS-800 Calibrated Densitometer. 
 
3.3.4 MMP-13 fluorimetric assay 
SensoLyte® 520 MMP-13 Assay Kit *Fluorimetric* was purchased from 
(Anaspec, Fremont, CA, USA). This kit is to detect MMP-13 activity using a 5-
FAM/QXL™520 FRET peptide as substrate, with its fluorescence monitored at 
Ex/Em=490 nm/520 nm upon proteolytic cleavage. The SensoLyte® 520 MMP-13 
Assay Kit provides a convenient assay for high throughput screening of MMP-13 
inducers and inhibitors. It also detects MMP-13 activity in a variety of biological 
samples using a 5-FAM/QXL™520 fluorescence resonance energy transfer (FRET)2 
peptide.  
The assay is able to detect as low as 3ng of MMP-13. The protein was initially 
activated with aminophenyl mercuric acetate (APMA) by incubating it at 37°C for 40 
min. Once the incubation was complete, the activated protein solution was aliquoted 
into different tubes and test compounds were added at concentrations 0, 25, 50 and 
100 nM and incubated for 2 hr. The following controls were also setup; 
1. Positive control contains MMP-13 diluent without any test compound. 
2. Inhibitor control contains MMP-13 and a known MMP-13 inhibitor 
79 
 
3. Vehicle control contains MMP-13 diluent and vehicle used in delivering test 
compounds (eg. DMSO). 
4. Test compound control contains assay buffer and test compound. Some test 
compounds have strong autofluorescence and may give false results. 
5. Substrate control contains assay buffer only. 
Note that MMP-13 substrate diluents solution was prepared with assay buffer in the 
ratio of 1:100. 
MMP-13 diluent solution of 50 μL (96-well plate) was added to each well and 
50 µL of activated protein with the drug compound. The reagents were mixed 
completely by shaking the plate gently for 30-60 sec. All reactions, including 
controls, were performed in duplicates. 
 A kinetic reading immediately start measuring fluorescence intensity at 
Ex/Em=490 +20 nm/520+20 nm respectively using Varioskan Flash (Thermo 
Scientific). 
 
3.3.5 Cell invasion assay 
 The BD BioCoat Tumor Invasion system is  a chamber that has a light-tight 
polyethylene terephthalate membrane with 8μm diameter  pores and is coated with a 
reconstituted basement membrane gel (BD Biosciences).  5x10
4
 MDA-MB-231 cells 
were suspended in serum free RPMI media and seeded into the Matrigel transwell 
chambers. The cells were pretreated with compound 5, 6 and known (WAY-170523), 
selective inhibitor of MMP-13 Hpx domain for 4 h. After incubation, the outer 
surfaces of the transwell chambers were wiped with cotton swabs and the invading 
cells were fixed and stained with crystal violet solution. The invading cells were then 
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counted in 5 randomly selected areas under microscopic observation as described 
previously (Manu et al., 2011). 
 
3.3.6 Clinical analysis of MMP-13 in breast and colon cancer 
 The content of the clinical section was generously been provided by Professor 
Jean Paul Thiery and Dr. Tan Tuan Zea from Cancer Science Institute of Singapore  
from Department of Biochemistry and Cancer Science Institute of Singapore, NUS 
  
3.3.6.1 Data pre-processing of microarray gene expression 
 Breast (n = 536) and colorectal cancer (colon, n = 155; rectum, n = 69) 
microarray dataset on Agilent G4502A_07 were downloaded from The Cancer 
Genome Atlas (TCGA; http://cancergenome.nih.gov) website.  Partek Genomic suite 
® version 6.6 was used to import the Agilent feature extraction file, and subsequently, 
the expression log ratio was quantile normalized and transformed to log 2 ratio. 
 
3.3.6.2 Identification of breast cancer subtypes 
 Breast cancer subtype signature was obtained from the reference (Prat et al., 
2010).  Subsequently, Single sample Gene Set Enrichment Analysis (ssGSEA) was 
computed based on the breast cancer subtype signature for each sample.  Each sample 
was then assigned to be the subtype that it has the maximum ssGSEA score. 
 
3.3.6.3 Epithelial-mesenchymal Transition Score 
 An Epithelial-Mesenchymal Transition (EMT) signature was developed by 
comparing expression profiles of CDH1 with CDH2 expressing ovarian carcinomas 
cell lines using Binary Regression method (Gatza et al., 2010).  The BinReg ovarian 
81 
 
cancer EMT signature was then applied to predict the EMT status of colorectal or 
breast cancer tumors.  Subsequently, the top 5% (~100 samples) with the highest 
probabilities for epithelial or mesenchymal phenotype were used to obtain the 
epithelial or mesenchymal specific gene list for the colorectal or breast cancer tumor 
(EMT signature) using Significance Analysis of Microarray (SAM) q-value =0 and 
ROC value of 0.85.  
 To obtain EMT score of a colorectal or breast cancer tumor, the enrichment 
scores of the colorectal or breast cancer tumor-specific epithelial and mesenchymal 
gene list were computed using Single Sample GSEA (Verhaak et al., 2010). EMT 
score is defined as the normalized subtraction of the mesenchymal from epithelial 
enrichment score.  A higher or lower EMT score indicate that a breast tumor exhibits 
a more mesenchymal or epithelial phenotype.  
 
3.3.6.4 Statistical analysis 
 Statistical significance evaluation by Mann-Whitney test and Spearman 
correlation test were computed using Matlab®.  Dot plot was done using Graphpad 
Prism. 
 
3.3.7 Isothermal titration calorimetry (ITC)  
For ITC experiments, Hpx in a buffer consisting of 50 mM Tris HCl pH 7.1, 
150 mM NaCl, 5 mM CaCl2 and 5% glycerol was titrated against the six lead 
compounds prepared by dissolving in the same buffer. The ITC experiments were 
carried out using VP-ITC calorimeter (Microcal) at 37°C using 0.02–0.04 mM protein 
in the sample cell and 150-300 µM of drug compounds in the injector. All samples 
were thoroughly degassed and centrifuged. Injection volumes of 8-10 μl per injection 
were used for each experiment; the heat of dilution for the ligand was measured. To 
82 
 
restore the baseline, successive injections were separated by at least 4 min. All ITC 





CHAPTER 4. RESULTS  
 
4.1 COMPUTATIONAL RESULTS 
4.1.1 Sequence-based analysis to identify putative characteristic functional 
 residues of the Hpx domain of MMP-13 
 We identified 34 characteristic residues for the Hpx domain of MMP-13 
(HCR-13) that were completely conserved and unique to the analyzed sequences of 
this domain (Fig. 24). Five (Lys318, Arg344, Arg346, Lys363 and Lys372) of these 
matched the 11 putative functional residues of MMP-13 Hpx domain (Gomis-Ruth et 
al., 1996) (these five are referred to as HCR-13pf). Binding of a ligand to as many of 
these HCR-13pf and possibly the remaining HCR-13 are postulated to result in 
increased selective inhibition of the Hpx domain of MMP-13. Through high 
throughput virtual screening (HTVS), we identified 25 ligands that interacted with at 
least one of the HCR-13pf. The ligands were screened from a large library of 16908 
molecules obtained from the public databases Maybridge, PubChem and Binding; all 
the identified 25 ligands were from Maybridge. 
The sequences of all reported human MMP proteins were extracted by 
performing PSI-BLAST (McGinnis and Madden, 2004) against the non-redundant 
(nr) protein database using the query sequence of MMP-13, which was obtained from 
the Protein Data Bank (Berman et al., 2000) (PDB ID:1PEX). A total of 50 MMP 
sequences were obtained from the BLAST search (supplementary Table 14). These 
sequences were then multiple sequence aligned using Muscle v3.6 (Edgar, 2004), and 
the resulting alignment was manually inspected and corrected for misalignments using 
BioEdit (Hall, 1999). The regions of the alignment representing the pro-peptide 
domain, catalytic domain and the linker region were deleted, leaving only the Hpx 
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domain. The total number of MMPs from each family out of 50 sequences is 
represented in (Table 5). 
 
Figure 24. The characteristic residues of the Hpx domain of MMP-13 (HCR-
13). The residues potentially important for the function of the domain (HCR-
13pf) are indicated with the green inverted triangles. The amino acid positions 
are with respect to the Hpx domain of the PDB record 1PEX. 
 
4.1.2 Docking results 
Docking analysis using the more precise XP mode of Glide revealed that the 
25 ligands formed hydrogen bonds with 1-3 residues of HCR-13, of which 1-2 were 
HCR-13pf. In addition, hydrogen bonds were also formed by 1-2 non-HCR-13, but 
putative functional residues and 1 non-HCR-13, non-putative functional residue 
(Table 6). 
Assessment of cross-reactivity of the 25 ligands with MMP-1 (containing both 
catalytic and Hpx domains) and MMP-8 (only catalytic domain), members of the 
collagenase family as MMP-13, returned seven lead molecules that did not bind to 
any one of the putative functional residues of Hpx domain of MMP-1 and any of the 
catalytic active site residues of MMP-1 and -8. Also, the closest distance between the 
functional residues of the Hpx (MMP-1) or the catalytic active site residues (MMP-1 
and MMP-8) to the lead molecules was more than 10Å (data not shown), suggesting 
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that the ligands are not likely to interact with the functional or catalytic residues. The 
docking results of the final seven lead molecules to 1PEX are given in Table 7. 
 
Table 4. Number of sequences of the various MMPs studied. These sequences 
were obtained from the NCBI Entrez protein database by use of PSI-BLAST 
search (as of May 2009). The number of sequences was obtained after editing in 
BIOEDIT. 
 

















Table 5. The 25 screened ligands that interacted with at least one residue of the HCR-13pf of MMP-13 (1PEX) and their hydrogen 
bond interaction to residues of MMP-1 (PDB ID: 1SU3, containing Hpx and catalytic domain) and -8 (PDB ID: 1BZS, with only 















(catalytic domain) (catalytic domain) (Hpx domain) 




GLU198, ALA161, LEU160 
11798 ARG344, ARG346, ASN326 GLN66, ASP96 - GLU198, ALA161, LEU160 
3764 ARG344, ARG346, LYS347, ASN326 LYS63, GLN66, 
ASP96 
- ALA161, LEU160 
9526 ARG344, LYS347,  ASN326 LYS63, GLN66, 
ASP96 
- GLU198, TYR216, PRO217 
764 ARG344, ARG300 GLN66, ASP96 - - 
12416 ARG344, ARG346, LYS347, ASN326 LYS63, GLN66 - GLU198, HIS207,  ALA161, 
LEU160 
13575 ARG344, ARG346, ASN326 ASP96 - GLU198, ALA161, LEU160, 
4199 ARG344, ARG346, ARG327, ASN326 LYS63, GLN66, 
ASP96 
- GLU198, PRO217 
11397 ARG344, ARG300 LYS63, GLN66, 
ASP96 
- GLU198, ALA161, LEU160 
7889 ARG344, ARG346, LYS347 ASP96 - GLU198, PRO217 
13196 ARG344, ARG300 GLN66 LYS425 HIS197, LEU160 
3705 ARG344, LYS347, ASN326 GLN66, ASP96 - ALA161 
4413 ARG344, ARG346, ASN326 LYS63, GLN66 - GLU198, LEU160 
6885 ARG344, ASN326 GLN66 LYS362 GLU198, ALA220 
8756 ARG344, ARG346 LYS63, ASP96 - GLU198, ALA161, LEU160 
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897  ARG344 ASP96 - GLU198 
632 ARG344, ASN326 LYS63, GLN66 - ALA161, PRO217 
14575 ARG346, LYS347 LYS63, VAL97, 
ASP96 
- GLU198, ALA161, LEU160 
14196 ARG344, ARG300, LYS347 LYS63, ASP96 - GLU198, ALA161 
3048 ARG344, ARG346, LYS347, ARG327, 
ASN326 
ARG91 TYR360, ARG341, 
ARG405 
GLU198 





7832 ARG344, ARG300, ASN326 GLN66 - GLU198, LEU160 
1698 ARG344, ASN326 LYS63, GLN66 - GLU198 
7789 ARG344, ARG346, LYS347 GLN66, ALA184, 
ASP96 
- ALA220 
1598 ARG344, ASN326 LSY63, GLN66 - ALA161 
 
 
a Ligand IDs are of the Maybridge database. 
b The HCR-13 amino acids are in boldface; HCR-13pf in boldface and underlined; functionally important residues of MMP-13 that 
are not part of HCR-13 are in non-boldface and underlined, residues not functionally defined and not part of HCR-13 are in 
italics. 
c The information for the catalytic active sites of 1SU3 and 1BZS was obtained from PDBSum database. Active site residues of the 
catalytic domain are in boldface. None of the active site residues of the catalytic domain and the putative functional residues of 




























ARG344 (1.491), ARG346 (1.963), LYS347 (1.869), ASN326 
(2.258)  
4 polar 
764 -9.07 ARG344 (2.037), ARG300 (1.689 and 1.821) 3 polar 
13196 -8.78 ARG344 (1.748), ARG300 (1.595 and 1.853) 3 polar 
3705 -8.74 ARG344 (1.833 and 1.967), LYS347 (2.412), ASN326 (1.903)  4 polar 
632 -8.08 ARG344 (1.923 and 1.877), ARG326 (1.830) 3 polar 
7789 -7.59 ARG344 (2.324), ARG346 (1.929), LYS347 (1.964 and 2.342) 4 polar 
1598 -7.55 ARG344 (1.468), ASN326 (2.048) 2 polar 
 
a Ligand IDs are of the Maybridge database. 
b Glide score. 
c The amino acids of the HCR-13pf that interact with the lead molecules are in boldface and underlined, while functionally important 
residues of MMP-13 that are not part of HCR-13 are only underlined. Residues not functionally defined and not part of HCR-13 are 
in italics. The hydrogen bond distances, in angstroms (Å), between the interacted amino acids of 1PEX and the seven lead molecules 
are indicated in brackets. 
d Number of hydrogen bonds formed. 

















Figure 25. Structure of the seven lead molecules. The Maybridge database ID 
of the lead molecules are as follows: compound 1 - 3764; compound 2 - 764; 
compound 3 - 13196; compound 4 - 3705; compound 5 - 632; compound 6 - 
7789; and compound 7 - 1598. 
 
The chemical name of the seven lead compounds with their corresponding 
Maybridge identity (ID) number are 2-fluoroisophthalic acid (compound 1: 3764), 3-
(carboxymethyl)-2-methylenepentanedioic acid (compound 2: 764), 2-{2-[(2-
chlorobenzoyl)amino]-1,3-thiazol-4-yl}acetic acid (compound 3: 13196), 6-hydroxy-
2-(methylsulfanyl)-4-pyrimidinecarboxylic acid (compound 4: 3705), 2,3-dihydro-
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1,4-benzodioxine-5-carboxylic acid (compound 5: 632), 1-acetyl-4-
hydroxypyrrolidine-2-carboxylic acid (compound 6: 7789) and 2,3-dihydro-1,4-
benzodioxine-2-carboxylic acid (compound 7: 1598). The chemical structures of these 
lead molecules are illustrated in Fig. 25. 
The structural scaffolds of the lead molecules contain carboxylic acid 
functional group, which is mainly responsible for the hydrogen bonds observed with 
the HCR-13pf. The binding conformation of the lead molecules with the hydrogen 
bond interactions to the Hpx domain of MMP-13 are given in Fig. 26. The short 
hydrogen bond distance, ranging from ~1.5 to ~2.4 Å, and the favourable binding G-
scores (-9.22 to -7.55 kcal/mol) (Table 8) suggested strong enzyme-ligand 
interactions. These carboxylic acid containing lead molecules were found to exhibit 
hydrophilic contacts with 1PEX, mostly with the polar side chains of amino acids 
Arg344 and Arg346 of HCR-13pf. They also exhibited polar interaction with other 
functionally important amino acid residues that are not part of HCR-13, namely 
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Compound 3 Compound 4 
  
















Figure 26. Binding poses of the seven lead molecules. The proposed binding 
mode of the lead molecules are shown in ball and stick display and non carbon 
atoms are coloured by atom types. Critical residues of binding are shown as 
lines colored by atom types. Hydrogen bonds are shown as dotted yellow lines 
with the distance between donor and acceptor atoms indicated. Atom type 
colour code: red for oxygen, blue for nitrogen, grey for carbon and yellow for 
sulphur atoms respectively. The HCR-13pf residues that interacted with the lead 
molecule are indicated by the arrow. The Maybridge database ID of the lead 
molecules are as follows: compound 1 - 3764; compound 2 - 764; compound 3 - 
13196; compound 4 - 3705; compound 5 - 632; compound 6 - 7789; and 
compound 7 - 1598. 
 
4.1.3 Bioavailability of the lead molecules 
In accordance with Lipinski’s rule of five, the Mobyle portal was used to 
evaluate the drug-likeness of the lead molecules by assessing their physicochemical 
properties. Their molecular weights were < 500 daltons with < 5 hydrogen bond 
donors, < 10 hydrogen bond acceptors and a log p of < 5 (Table 8); these properties 
are well within the acceptable range of the Lipinski rule for drug-like molecules. 
These compounds were further evaluated for their drug-like behaviour through 
analysis of pharmacokinetic parameters required for absorption, distribution, 
metabolism, excretion and toxicity (ADMET) by use of QikProp. For the seven lead 
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compounds, the partition coefficient (QPlogPo/w) and water solubility (QPlogS), 
critical for estimation of absorption and distribution of drugs within the body, ranged 
between ~ -0.1 to ~ 2.3 and ~ -4 to ~ -0.05, cell permeability (QPCaco), a key factor 
governing drug metabolism and its access to biological membranes, ranged from ~ 26 
to ~ 276, while the bioavailability and toxicity were from ~ 3.4 to ~ 0.4. Overall, the 
percentage human oral absorption for the compounds ranged from ~ 46 to ~ 79%.  
 








3764 764 13196  3705 632 7789 1598 
    
 
 
   
MW 182.1 185.1 170.1  185.1 179.1 172.1 179.1 
Drs 0 0 0  1 0 1 0 
Ars 4 5 4  5 4 5 4 
FB 4 8 3  3 2 3 2 
RB 8 4 9  7 12 7 12 
#R 1 0 2  1 2 1 2 
RL 6 0 5  6 6 5 6 
C 8 7 5  6 9 7 9 
nC 5 6 7  6 4 5 4 
C/nC 0.63 0.86 1.40  1.00 0.44 0.71 0.44 
#Chrg 2 3 1  1 1 1 1 
chrg -2 -3 -1  -1 -1 -1 -1 
LogP 0.53 -2.36 -1.17  0.14 0.82 -1.59 0.73 
PSA 73.94 110.91 82.86  108.28 55.43 77.51 55.43 
 
a Abbreviations: MW - Molecular weight, Drs - Hydrogen donors, Ars - 
Hydrogen acceptors, FB - Flexible bonds, RB - Rigid bonds, #R - Ring number, 
RL-Ring size, C - Number of atoms, nC - Atom number, C/nC - Ratio 
carbon/hetero, #Chrg - Charge number, chrg - Total charge, LogP -Partition of 
co-efficient, and PSA - Polar surface area. 
b Ligand IDs are of the Maybridge database. 
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0.841 -1.388 70.704 0.219 47.742 
764 
 
2.239 -3.622 78.429 2.381 30.962 
13196 
 
2.239 -3.622 78.428 -3.382 73.962 
3705 
 
1.058 -1.740 44.646 -1.559               62.677 
632  1.409 -1.558 276.206 -1.496 78.888 
7789  -0.967 -0.051 26.073 0.351 47.633 
1598  1.454 -1.630 249.077 -1.869 78.349 
 
a
Ligand IDs are of Maybridge database. 
b
Predicted octanol/water partition co-efficient log p (acceptable range: -2.0 to 
6.5). 
c
Predicted aqueous solubility; S in mol/L (acceptable range: -6.5 to 0.5 ). 
d
Predicted Caco-2 cell permeability in nm/s (acceptable range: < 25 is poor and 
> 500 is great). 
e
Predicted IC50 value for blockage of HERG K+ channels (acceptable range: 
below -5.0). 
f
Percentage of human oral absorption (< 25% is poor and > 80% is high). 
 
All these pharmacokinetic parameters are within the acceptable range defined 
for human use (see Table 9 footnote), thereby indicating their potential as drug- like 
molecules. 
As of May 2010, the number of MMP sequences in the NCBI Entrez protein 
public database almost doubled since our last data collection (May 2009). The May 
2010 data contained a total of 94 MMP sequences, an increase of 44 since May 2009. 
Analysis of the 94 sequences revealed that the number of HCR-13 residues 
(completely conserved and unique to MMP-13) reduced significantly from 34 to only 
10 (Gln309, Ala312, Lys318, His334, His337, Arg344, Asn352, Lys372, Ser378, and 
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Glu373), whereas the HCR-13pf reduced from 5 to 3 (Lys318, Arg344, and Lys372). 
This was expected because of our small initial sample size. Nonetheless, there was no 
change in the HCR-13pf residues bound by our seven lead molecules, except for two 
(compound 1and 6 where the residue Arg346 that interacted with both is no longer 
HCR-13pf), however even these still bound to one HCR-13pf residue. 
 
4.2 IN VITRO AND IN VIVO RESULTS 
4.2.1 Basal level expression of MMP-13 of breast and colon cancer cell lines 
 MMP-13 was found to be expressed predominantly in breast and colon cancer 
cell lines. A basal level expression study on various breast and colon cancer cell lines 
was first performed to determine basal expression of MMP-13 in these cell lines. It 
has been revealed that MMP-13 is highly expressed in MDA-MB-231 among breast 
and equally expressed in SW-480 in colon cancer cell lines respectively as shown in 
Fig. 27. Hence this particular cell line was chosen to carry out all our further cell 
culture experiments with generous support from Dr. Alan Perm Kumar lab, 
Department of Pharmacology, NUS. 
 
Figure 27. Basal level expression of breast and colon cancer cell lines, detected 
by western blot with an anti-MMP-13 antibody raised in rabbit.  





4.2.2 Cell viability assay 
From the basal level study herein all six drugs (we could not purchase the 
seventh compound) were tested for their cytotoxicity using the (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) MTT 
assay with a range of 1, 10 and 100 µM concentration, respectively on the MDA-MB-
231 breast cancer cell line. The viability of the cell was determined at 48 (Figs 28A 
and B) and 72 hr, (Figs. 28C and D) respectively. Their corresponding IC50 values are 
given in Table 9. 
  
  
Figure 28. (A) and (B) MTT assay for six drug-like molecules at 48 hr. (C) and 
(D) MTT assay at 72 hr respectively. The assay for six drug-like molecules at 
48 and 72 hr; the X-axis denotes the concentration of each compound at 
different concentrations, whereas y-axis was the absorbance readings at 490nM 
respectively. The y-axis denotes the percentage of survival of the MDA-MB-
231 cells that were used for this assay. The p-value was computed by one way 
MTT assay at 48 hours
























MTT assay at 48 hours
























MTT assay at 72 hours
























MTT assay at 72 hours


























ANOVA test using GraphPad Prism. No significant difference was observed 
(p>0.05).  
 
Table 9. IC50 values of six lead compounds using cell viability assay 








cpd1  23.04  21.75  
cpd2  29.99  27.19  
cpd3  27.36  19.72  
cpd4  19.25  25.79  
cpd5  25.44  21.82  
cpd6  15.42  19.82  
 
No cytotoxicity was observed in untreated cells (control UnC) as well as those 
treated with the compounds. However compounds 4 and 5 show minimal toxicity 
when compared to the untreated control (UnC). The relative fluorescence units (RFU) 
versus concentration were plotted using the GraphPad Prism (GraphPad) software. 
 
4.2.3 Fluorimetric based MMP-13 inhibition assay 
The activity of the MMP-13 enzyme was assayed without and with the lead 
compounds. The six lead compounds were tested against the MMP-13 activity using 
SensoLyte® 520 MMP-13 Assay Kit along with a positive control of MMP-13 
selective inhibitor WAY-170523 (purchased from Tocris Bioscience, UK), which has 
an IC50 of 17 nM. Initially the compounds were tested in a broad range of 
concentration, 0, 25, 50, 75 and 100 µM at 2, 4 and 8 hr, respectively.  
 The kinetic fluorescence readings of the incubated enzyme with the six drug-
like molecules were obtained at Excitation/Emission at 490 +20 nm/520+20 nm at 
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different time points ranging from 2, 4 and 8 hr, respectively. The results are plotted 
using GraphPad Prism. Compounds 5 and 6 exhibited a significant decrease (at 2 and 
4 hr respectively) in MMP-13 activity as shown in Fig. 29. However after 8 hr the 
compounds and the positive control saturated. The IC50 values for all six compounds 







Figure 29. Fluorimetric based inhibition of MMP-13 by six drug compounds 
analysed at 2, 4 and 8 hr respectively. Maximum MMP-13 activity inhibition by 
MMP-13 substrate was observed at 4 hr of incubation with the activated enzyme 
by all six drug-like compounds with a range 0, 25, 50 and 100 µM 
concentrations for each of them respectively. The x-axis denotes the 
concentration of each compounds in terms of micromolar and y-axis is the 
relative fluorescence intensity was obtained at Ex/Em=490 +20 nm/520+20 nm. 
The p-value was computed by one way ANOVA test using GraphPad Prism.  












Concentration of compounds (µM)  
MMP-13 activity at 2 hrs















Concentration of compounds (µM)  
MMP-13 activity at 4 hrs


















Concentration of compounds (µM)  
MMP-13 activity at 8 hrs





(WAY-170523). Those p-values <0.05 are indicated in (*) at the top of errors 
bars. 
  
Table 10. IC50 values for six lead compounds obtained from fluorimetric assay at 2, 4 
and 8hr respectively 
Compounds  2hr (μM) 4hr (μM) 8hr (μM) 
Cpd1  96.78 41.42 -  
Cpd2  98.43 35 -  
Cpd3  99.76 97 -  
Cpd4  98 42.31 -  
Cpd5  43.22 21.91 42.18 
Cpd6  43.5 23.3 40.43 
WAY-170523  43.57 11.87 30.95 
  
Based on these confounding results, as the saturation point of drugs are not clear from 





concentrations, in steps of 10 fold decrease for compounds 5, 6 and the positive 
control. The results are shown in Fig. 30. It is clear that compounds 5 and 6 have 
immediate response over MMP-13 activity within 10 min. However after 10 min, the 
deviation between the positive control and compounds 5 and 6 becomes high. The 
graphs for 20, 30, 40 min, 2hr and 3 hr are given in supplementary Fig.44. 
As these inhibitors are targeted to Hpx domain of MMP-13 and the positive control is 
for the full length MMP-13 protein, hence the rate of inhibition might be different. 
The IC50 values for each of the compounds are given in Table 11. 
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Figure 30. Fluorimetric based inhibition of MMP-13 by the drug compounds 5, 
6 and known inhibitor (WAY 170523) of MMP-13. The compounds were tested 





concentrations, in steps of 10 fold decrease (compared to previous assay at 2, 4 
and 8hr) for compounds 5, 6 and the positive control. The inhibitory activity of 
the test compounds and the known inhibitor was found to be maximum at 10 
min. After 2 hr the compounds started to get saturate and also the deviation 
between the compounds towards the known inhibitor was quite high after 3 hr 
(data for other time intervals are shown in supplementary Fig. 44. This is due to 
that the test compounds still show their inhibition beyond 3 hr whereas the 
known inhibitor not. Here x-axis denotes the concentration of the compounds in 
micro molar; y-axis denotes the relative fluorescence intensity (RFU) of MMP-
13 substrate (FRET) cleaved in the presence of activated MMP-13. The RFU is 
observed at Ex/Em=490+20 nm/520+20 nm.  















































Dose dependent inhibition of MMP-13 of compound 5 and 6 (IC50 [µM]), at various 
time points.  
 
4.2.4 Heparin-enhanced zymographic detection of MMP-13 
 From the MMP-13 assay results it was found that compound 5 and 6 exhibit 
better inhibitory activity and hence these compounds were used for heparin-induced 
zymographic detection of MMP-13. The results are provided in Fig.31. 1mg/ml 
gelatin was digested by 80µg of culture supernatant. The relative density and 
percentage of inhibition with respect to control is given in supplementary Table 15. 
Time point
a
 cpd5 (μM) cpd6 (μM) 
Known inhibitor 
(WAY-170523) (μM) 
10mins 0.02 0.36 0.02 
20mins 0.76 0.54 0.02 
30mins 2.78 0.31 0.03 
40mins 2.87 0.32 0.04 
1hr 1.16 0.22 0.05 
2hr 2.65 0.23 0.05 




Figure 31. Heparin-enhanced detection of MMP-13 activity using gelatin 
zymography. The above black rectangular box showing the percentage 
inhibition of gelatin heparin-induced zymographic detection of MMP-13; Lane-
1, Control; Lane-2 – 100μM compound 5; Lane-3, 100μM compound 6; Lane-4, 
100μM  known MMP-13 inhibitor; Lane-5,  Protein standards.  
 
4.2.5 Cell invasion assay 
 From the invasion assay it was clearly seen that compounds 5, 6 exhibited less 
invasion than known (WAY-170523). However it is not certain that whether the 
inhibition is due to MMP-13 or MMP-9. In order to confirm this knockdown of 
MMP-13 with appropriate siRNA would highlight the specificity of these compounds. 
 
Figure 32. BD-Biomatrigel cell invasion assay of MDA-MB-231 in the presence of 
compounds 5, 6 and Known. MDA-MB (5 × 10
4
 cells) was seeded in the top-chamber 
of the Matrigel. After pre-incubation with RPMI media for one hour the transwell 
chambers were then placed into the wells of a 24-well plate, in which we had added 




A – Control MD-MBA-231 B – Compound5













































incubation, they were assessed for cell invasion as described in Materials and 
Methods. Columns indicate mean percentage of invaded cells; bars, S.E. *, P < 0.05 
and n=2. 
 
4.3 MICROARRAY RESULTS (AGLIGENT MICROARRAY 
 PLATFORM) 
 The data obtained from Prof.John Paul Theary This supports the identification 
of MMP-13 in breast and colon cancer (refer Introduction, Section 1.4 under the 
heading “MMPs A TARGET FOR DRUG DEVELOPMENT”). 
4.3.1 MMP-13 expression in breast and colon cancer 
 Colorectal and breast carcinoma on Agilent microarray platform were 
downloaded from The Cancer Genome Atlas (TCGA; see Materials and Methods; 
data from Prof. John Paul Theary and Dr. Tan Tuan Zea from University of Texas).  
The correlation of MMP-13 expression level and clinic-pathological parameters of 
colorectal and breast carcinoma is given in supplementary Figs. 45 and 46 
respectively. 
 In colorectal carcinoma, MMP-13 has little correlation with carcinoembryonic 
antigen (CEA) level (supplementary Fig. 45 A; Spearman correlation Rho = 0.103, p 
= 0.2524), an antigen often elevated and is associated with metastatic spread in 
colorectal cancer (Prat et al., 2010). This suggests a role of MMP-13 in colorectal 
tumor aggressiveness.  In support of our conjecture, MMP-13 expression level is 
found to be significantly higher in more aggressive and resistant mucinous colon 
adenocarcinoma than regular adenocarcinoma (Nozoe et al., 2000) (supplementary 
Fig. 45 B; Mann-Whitney test, p = 3.74e-5). Since MMP-13 may have a role in tumor 
aggressiveness, we then investigate the relation of MMP-13 and staging or Epithelial-
Mesenchymal Transition (EMT; see supplementary Fig. 45 C, D).  Although there is 
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no significant correlation with tumor staging, MMP-13 correlate significantly with 
EMT score (Spearman correlation Rho = 0.4468, p = 3.6e-12), implicating a role in 
tumor aggressiveness, in concordance of MMP-13 correlation with CEA level and 
elevated level of MMP-13 in mucinous adenocarcinoma. 
 Paradoxically, gene expression of MMP-13 was significantly lower in basal 
and claudin-low breast carcinoma subtypes (Mann-Whitney test, p = 8.35e-06, and p 
= 0.06) that are known to be more aggressive (Elsawaf and Sinn, 2011), as shown in 
supplementary Fig. 46 A.  MMP-13 is significantly higher in Luminal B, and ERBB2 
breast cancer subtypes (Mann-Whitney test, p = 0.045 and p = 0.0069, respectively), 
but not in Luminal-A (Mann-Whitney test, p = 0.2958). As for Normal-like subtype, it 
has significantly lower expression than the other subtypes (Mann-Whitney test p = 
0.031).  Consistently, in supplementary Fig. 46 B we see that MMP-13 is significantly 
lower in ER negative, PR negative, and is significantly higher in HER2+ breast 
carcinoma (Mann-Whitney test, p = 0.0658, p = 0.0121, and p = 0.0303, respectively). 
Similar to colon carcinoma, there is no significant correlation of tumor staging with 
MMP-13 expression in breast carcinoma (supplementary Fig. 46 C). As MMP-13 is 
significantly lower in ER negative breast cancer, in contrast to colorectal carcinoma, 
suggests that MMP-13 may have no role in tumor aggressiveness in breast cancer, as 
supported by observation that no correlation of MMP-13 gene expression with EMT 
score (supplementary Fig. 46 D; Spearman correlation Rho = -0.0012, p = 0.9774). 
 
4.4 STRUCTURAL RESULTS 
Based on the computational and experimental validation of the drug 
compounds, we further wished to crystallographically verify the molecular 
interactions obtained from our docking study. We co-crystallized the lead molecules 
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with the Hpx domain of MMP-13. We determined the apo Hpx structure of MMP-13 
and the inhibitor densities are still elusive, as explained later. In addition, 
crystallization trials are underway for the full length enzyme. 
 
4.4.1 Crystallization of Hpx domain of MMP-13 
The HPX domain of the MMP-13 protein was expressed and purified as 
explained in the Materials and Method section. In short, the Hpx domain (residues 
274-471) was cloned in the pETM vector, expressed as in insoluble protein in E. coli 
(BL21), first purified with the Ni-NTA resin, refolded by rapid dilution and again 
purified by gel filtration using an S75 column. 
Fig. 32 shows SDS-PAGE of the affinity purification results and Fig. 33 
shows the gel filtration results. Fig. 34 shows the presence of the HPX protein in the 
gel filtration fractions and the protein size (by SDS-PAGE) was confirmed by mass 
spectrometry. The homoeneity of the protein was further analysed using dynamic light 
scattering (DLS) (Fig. 36). However the results indicated presence of some small 
amount of aggregates in the Hpx protein sample as shown in Fig. 34. And the crystals 











Figure 33. Ni-NTA affinity purification of Hpx domain of MMP-13 was shown 
in the above SDS gel which is of 25 kDa size. Lane-1, protein marker; Lane-2, 
flow throw; Lane-3, 4 and 5, wash 1, 2 and 3; Lane-6, 7 and 8, eluted protein 1, 
2 and 3. 
 
 
Figure 34. Gel filtration profile of Hpx when loaded onto a size-exclusion 75 
column. The above graph is the FPLC graph and the peak showing the protein is 
between 70 and 80 ml. Peak corresponding to 40 and 60 ml are the protein 
aggregates. 
  
Figure 35.  SDS gel showing the FPLC fractions of Hpx domain of MMP-13. 









the presence of MMP-13 Hpx corresponding to 25 kDa. Lane-1 corresponds to 





Figure 36. Dynamic light scattering (DLS) of Hpx domain of MMP-13. The 
Polydispersity index, MW and SOS error are in red, green and blue boxes 
respectively. The above values had deviated from the threshold values. This is 
due to the presence of protein aggregates that has been formed during refolding 
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process. This experiment (DLS) was carried several times with varying 
concentrations of the proteins to get better DLS parameter values. 
 
 
Figure 37. Hpx crystals 
 
4.4.2 Structure determination of apo Hpx of MMP-13 
Our crystallization attempts with the above Hpx protein sample using the 
hanging drop method, Hampton crystal screens 1 (condition 4 containing 0.1 M Tris 
HCl pH 8.5 and 2.0 M ammonium sulphate) produced crystals of size with length 0.4 
to 0.6 mm in 2 days by. The crystals belong to the space group P3221 with unit-cell 
parameters are a = 52.146, b= 52.146, c = 144.605 Å,  Matthew’s co-efficient 2.25 
Å3/Da, solvent content 45.46% (Matthews, 1968) and one molecule in the 




Figure 38. A sample diffraction image of the apo Hpx crystal. 
 
A crystal of suitable size was flash cooled under cold N2 stream at 100 K 
using 50% glycerol as cryo protectant. The native crystals diffracted upto 2.1 Å 
resolution, Fig. 37 at the Taiwan Synchrotron, beamline BL13B1, ADSC Q315 
detector.  Data were processed and scaled using the HKL2000 (Otwinowski and 
Minor, 1997). The structure of the apo Hpx domain was solved by the molecular 
replacement method using MOLREP/CCP4 (Vagin and Teplyakov, 2010) with the 
MMP-13 Hpx (PDB ID:1PEX) as a search model. The structure was refined using 
Refmac (Murshudov et al., 1997). The overall geometry of the final model was 
analyzed by PROCHECK (R. A. Laskowski and Thornton). The crystallization and 
refinement statistics are provided in Table 12 and the structure was represented using 
PyMOL in Fig. 38. 
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Table 12. Crystallographic data and refinement statistics of Hpx domain 
 
Cell parameters (Å) 
a = 52.001, b=52.001  
and c = 144.017 
Space group  P3221 
Resolution range (Å)  50-2.3(2.30-2.35)* 
Wavelength (Å) 1.0 
Oscillation angle 1.0 
No. of images 180 
Observed reflections 126636 
Unique reflections 13609 
Redundancy 4.3  
% Completeness  100 [98.84]*  
Overall (I/ σ (I) 7.3 [2.3]* 
Rsym  0.08 [0.54]*  
Resolution range (Å)  50-2.3(2.30-2.35)*  
Resolution bin (Å)  2.35-2.30  
R-value  0.24  
Rfree  0.27  
RMSD bond length 0.02 
RMSD bond angle 1.21  
Ramachandran plot  
Most favoured regions 
Allowed regions 






Rsym = Σ|Ii – <I>|/|Ii| where Ii is the intensity of the ith measurement, and <I> is 
the mean intensity for that reflection.  
b
The R-factor (sometimes called residual factor or reliability factor or the R-
value or R-work) is a measure of the agreement between the crystallographic 
model and the experimental X-ray diffraction data. In other words, it is a 
measure of how well the refined structure predicts the observed data.  
c
Small subset of randomly selected reflections that are set aside (usually 5%) 
from the beginning and not used in the refinement of the structural model. Thus 
Rfree tests how well the model predicts experimental observations that are not 
themselves used to fit the model.  
 




Figure 39. Structure of Hpx domain of MMP-13. (A). Sequence length of 
different domains of MMP-13 are represented in green (signal peptide), red 
(catalytic domain) and purple (Hpx domain) respectively. (B). Three 
dimensional structure of Hpx domain of MMP-13. Cartoon representation of 
MMP-13 C-terminal domain (CTD) shown against the exit side of the disk. The 
CTD disk is slightly tilted with respect to the central pseudo 4-fold symmetry 
axis of the b-propeller structure to clarify the tracing of the ions in the central 
funnel-like tunnel. The four propeller blades are numbered (I to IV), and the 
four assigned ions in the tunnel are displayed as spheres (cyan for chloride 
anions, orange for calcium cations and magenta for sulphate ions) and 
disulphide bonds yellow in colour are represented in spheres . The location of 
the b-bulges in blades II and III is further indicated. Β-strands are displayed as 
arrows in yellow color and helical segments in red color. (C). Topology diagram 
of Hpx domain showing beta propeller blades with β-sheets with broad arrows 
with magenta colour and helices with cylindrical shape in red colour. 
 
Signal peptide Catalytic domain Hemopexin domain










4.4.3 Structure determination of Hpx-drug complexes 
We used 0.1-5mM drugs in DMSO for compounds 1-6 for co-crystallization. 
While crystallization trials produced diffraction quality crystals (2.7-2.1 Å resolution 
data were collected), no significant density for the drug molecules could be observed 
at the expected pocket. Our isothermal calorimetry (ITC) results, vide infra, show that 
the Kd values of protein-drug interaction are in the micromolar range, indicating the 
interactions are relatively weak. Furthermore, the high slat concentration of 
crystallization also could be major reason for shielding the drugs from strong binding 
with the protein. However the electron density for the putative functional residues of 
MMP-13 Hpx domain that predominantly binds to the seven lead molecules are 
shown in Fig. 39. 
 
Figure 40. Stereo diagram showing the electron density of the  putative 
functional residues of MMP-13 Hpx domain (HCR-13pf) that has interacted with 
the seven lead molecules are represented from the crystal structure of c-terminal 
domain of Hpx. All backbone atoms are represented in standard atom color, the 
electron density is represented in grey and the 4 amino acids are numbered as 1-
ASP326; 2-ARG344; 3-LYS347; ARG-346. The red arrows indicating the 





4.4.4 Crystallization of full length of MMP-13 
The full length MMP-13 protein was cloned in the pET32a vector and 
expressed in E. coli (BL21) cells and purified, as explained earlier. Fig. 40 shows the 
steps of affinity purification with Ni-NTA resin. The affinity purified protein was 
further purified by gel filtration (Fig. 41) and the monomeric fractions corresponding 
to the gel filteration peak was checked using SDS-PAGE (Fig. 42) and the molecular 
weight was verified by mass spectrometry. 
 Initially micro crystals of full length MMP-13 was obtained from Hampton 
crystal screen 2, condition 43 containing 0.1 M Tris HCl pH 8.5, 2.0 M ammonium 
phosphate monobasic and 100% (v/v) 2-methyl-2,4-pentanedio (MPD). However 
crystals of optimum size were unable to get. Further crystal optimization attempts are 
underway, including with additive as well as grid screens.  
 
 
Figure 41. Ni-NTA affinity purification of full length MMP-13 (55 kDa) 
showing on to SDS gel corresponding to 70 kDa size including the thioredoxin 











Figure 42. Gel filtration profile of full length protein on to a size-exclusion 200 
column. The above graph is the FPLC graph and the peak showing the protein is 
between 60 and 75ml. Aggregate peak showing at 40 and 60 ml.  
 
Figure 43. SDS gel showing the FPLC fractions of the refolded protein run on 
an s200 gel filtration column. The above fraction (D8-11) which corresponds to 
the monomeric peak shows the presence of full length of MMP-13 protein 











4.4.5 Isothermal titration Calorimetry (ITC) 
In order to understand the thermodynamic properties of the interaction 
between the Hpx domain of MMP-13 and the identified inhibitor drug molecules, we 
performed isothermal titration calorimetry (ITC) experiments.  
 Stock solutions of drug compound, prepared in 50% DMSO and at 100 mM 
concentration, was added to the Hpx protein in buffer containing (50 mM Tris HCl 
pH 7.2, and 150 mM NaCl). The concentration of Hpx versus drug compounds was 
given in the ratio of 1:10 (i.e 25 µM of Hpx to 250 µM drug compounds). A control 
ITC was run with 50% DMSO in the syringe versus buffer in the cell. The effect of 
this control experiment was subtracted from all original data before data-fitting.  
 
Table 13. ITC for six lead compounds. Thermodynamic data for the formation 







   
[kcal/mol] 
     
[kcal/mol] 
   
[kcal/mol] 
Cpd1 0.03 -20.8  -12.5 -8.25 






































Cpd4 0.13 -90.3 -80.1 -10.8 
Cpd5 0.7 -101.2 -88.8 -12.4 
Cpd6 0.8 -2.3 -6.0 -8.3 
 
[a] Errors are about 10%. Kd is the dissociation constant;    is enthalpy;      




















Figure 44. ITC profile for six inhibitors (compounds 1-6) with Hpx domain of 
MMP-13. The panels showed here is the integration (heat release) for each 
injection. The solid dots indicates the experimental data and the best fit to the 
experimental data were obtained from non-linear least square method of fitting 
using a one-site binding model for all compounds except for compound 2 and 3 
(which was a 2 sequential binding sites each) respectively. The binding 
constants (Kd), free enthalpies of binding (ΔG), enthalpies (ΔH), and entropies 
(ΔS) were obtained by curve fitting within errors of 10%. Compound 2 and 3 
were fitted with multiple (2) binding sites while other compounds showed 
single binding site, Fig. 43. Following our supporting evidence from our MMP-
13 assay and Zymography experiments, the ITC results also support that 
compound 5 and 6 exhibit relatively a strong binding affinity among the 








CHAPTER 5. DISCUSSION AND FUTURE DIRECTION 
 
5.1 DISCUSSION 
Matrix metalloproteinase-13 (MMP-13) has been a target for therapeutic 
development for cancer and other inflammatory disorders for a while. Recent studies 
have produced many broad spectrum inhibitors against various types of MMPs. 
However due to lack of selectivity, these inhibitors, mainly targeting the catalytic 
domain and non-zinc binding regions of MMP, lead to several side effects such as 
joint stiffness and musculoskeletal syndrome (MSS). Furthermore, due to sequence 
and structural similarities among the subfamilies of MMPs, the inhibitors that are 
directed towards the catalytic domain of MMPs lead cross reactivity with other MMPs 
also. Recent studies suggest that selective inhibition of MMP-13 may be achieved by 
targeting the C-terminal Hpx domain of the protease, which is critical for substrate 
specificity and necessary for the cleavage of type II collagen in osteoarthritis (OA), 
rheumatoid arthritis (RA) and cancer. Considering the above facts and limitations, this 
is the first study we identified selective inhibitors targeting the c-terminal Hpx domain 
of MMP-13.  
This study has contributed two significant findings: Firstly, we identified 34 
characteristic residues in the Hpx domain of MMP-13 (HCR-13) that were completely 
conserved and unique. From these residues, a subset of five residues, Lys318, 
Arg344, Arg346, Lys363 and Lys372, are referred to as putative functional residues 
of MMP-13 Hpx domain (HCR-13pf). Binding of a ligand to as many of the HCR-13pf 
is postulated to result in an increased selective inhibition of the Hpx domain. 
Secondly, for the first time using cheminformatics we identified seven selective drug-
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like molecules against Hpx of MMP-13. These drug-like molecules were tested for 
their efficacy to be potential inhibitors against MMP-13.  
 Twenty-five ligands were first identified from 16908 molecules from the 
Maybridge, PubChem and Binding libraries to interact with at least one of the HCR-
13pf through in silico structure-based high-throughput virtual screening (HTVS) with 
the Glide program. Elimination, based on cross-reactivity with MMP-1 and MMP-8, 
in silico pharmacokinetic analysis based on Lipinski’s rule of five and absorption, 
distribution, metabolism, excretion and toxicity (ADMET) properties resulted in the 
final seven inhibitors.  
 MMP-13 is over expressed in many cancers, and in this study we concentrated 
on breast and colon cancer. High protein expression was identified in the breast 
cancer cell line MDA-MB-231 and the colon cancer cell line SW-480. We chose 
MDA-MB-231 for our further experiments. The clinical data provided by Prof. Jean 
Paul Thiery and Dr. Tan Tuan Zea from University of Texas, shows the expression of 
MMP-13 at different tumor stages of breast and colon cancers. Through statistical 
analysis the authors have proved that MMP-13 expression level is found to be 
significantly higher in more aggressive and resistant mucinous colon carcinoma than 
regular adenocarcinoma. Based on their findings they conclude that however MMP-
13 is highly expressed in both breast and colon carcinomas, there is no significant 
difference in correlation with tumor staging between breast and colon carcinomas 
with MMP-13 expression.  
  Based on the above data herein our further experiments were carried in MDA-
MB-231 cell lines. The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay with six lead compounds showed that the MDA-MB-231 cells were 90% 
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viable upto 72 hr. Based on this we identified that all six drug compounds does not 
exhibit any toxicity to the MDA-MB-231 cells.  
 The six lead compounds were characterised for their inhibitory efficacy using 
a fluorimetric based inhibitory assay for MMP-13. The maximum inhibitory activity 
of compounds 5 and 6 against MMP-13 was identified at 10 min which is equivalent 
to the positive control (WAY-170523 specific MMP-13 inhibitor) inhibitory activity. 
However compounds 5 and 6 tend to saturate after 8 hr, and due to this the deviation 
of compounds 5 and 6 from the positive control is relatively high, likely due to the 
differences of their target domains. However, these new drug inhibitors should not be 
compared with the existing inhibitors of MMP-13, as there are no reported inhibitors 
for the Hpx domain of MMP-13. 
 On the other hand heparin-enhanced detection of MMP-13 activity using 
gelatin zymography shows that compounds 5 and 6 exhibit relative inhibitory activity 
on gelatin digestion along with WAY-170523 (positive control). Moreover the cell 
based invasion assay also clearly shows that compounds 5 and 6 exhibit better 
invasion capacity than known (WAY-170523). 
 Thermodynamic data (ITC) of compounds 5 and 6 show relatively better 
binding affinity (Kd) when compared to others in the isothermal titration calorimetry 
study. This supports our previous study on fluorimetric based inhibition on MMP-13 
activity and heparin-enhanced MMP-13 gelatin zymography assays that compound 5 
and 6 could serve as potential inhibitors against MMP-13. 
 In our crystallographic data with complex crystals of Hpx with the lead 
compounds, we could not observe density for the inhibitors in the complex crystals. 
We speculate that that the inhibitors could not strongly bind to the protein in the high 
salt concentration of the crystallization buffer.  
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 Hence we believe that their backbone structural scaffold could serve as 
building blocks in designing drug-like molecules for OA, RA and other inflammatory 
disorders that may overcome the limitations of other inhibitors targeting the zinc and 
non-zinc regions of the catalytic domain of MMP-13.   
 
5.2 FUTURE DIRECTIONS 
We have identified seven distinct drug-like molecules that bind to the HCR-
13pf of MMP-13 with no observable cross-reactivity to MMP-1 and MMP-8 (from 
cheminformatics study). These molecules are potential selective inhibitors of MMP-
13 and we have experimentally validated their effectiveness. Their backbone 
structural scaffold could serve as building blocks in designing drug-like molecules for 
osteoarthritis (OA), rheumatoid arthritis (RA) and other inflammatory disorders. 
 Using high-throughput virtual screening (HTVS) more specific lead 
compounds can be screened against the Hpx domain of MMP-13. In addition, the 
identified seven drug-like molecules were screened for cross reactivity against the 
collagenase subfamily. They should be cross validated against all 26 subtypes of 
MMPs using in vitro and in vivo studies.  
 The seven inhibitors interact with the putative functional residues of MMP-13 
Hpx domain (HCR–13pf). Site directed mutagenesis should be performed to learn 
more about these characteristic residues. Moreover the seven drug-like compounds 
should be tested in a mouse model with induced breast cancer to analyse whether 
these inhibitors overcome MSS syndrome and also inhibit MMP-13 appropriately.  
 More crystallization trials should be undertaken to determine protein-ligand 
interaction. This could render a better picture of molecular interactions between the 





Table 14. NCBI Entrez protein database accession and GI numbers of the 50 
MMP homologous sequences.  
 




















































































2876.577 27.581 0.523259 47.67406564 
Compound 6 
treated 
1615.335 15.488 0.293834 70.61658129 
















Figure 45. Fluorimetric based inhibition of MMP-13 by the drug compounds 5, 
6 and WAY 170523 (specific inhibitor of MMP-13). The compounds were 
tested at different time intervals ranging between 10 minutes to 3 hr. However 
the deviation between the compounds towards the known inhibitor was minimal 
initially at 10 min, and started to get saturated after 3 hr. And the deviation 
between the test compounds and the known also increased drastically. Here x-
axis denotes the concentration of the compounds in micro molar; y-axis denotes 
the relative fluorescence intensity (RFU) of MMP-13 substrate (FRET) cleaved 
in the presence of activated MMP-13. The RFU is observed at Ex/Em=490+20 
nm/520+20 nm.  
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Figure 46. Clinical data of MMP-13 expression level in colorectal cancer. (A) 
Pre-treatment and pre-operative Carcinoembryonic Antigen (CEA) level and 
gene expression level of MMP-13. CEA level is presented in log10 scale as y-
axis whereas MMP-13 is the x-axis. There is no significant correlation 
(Spearman correlation, Rho = 0.103, p = 0.2524). (B) Dot plot of MMP-13 
expression level in adenocarcinomas and mucinous histologies. MMP-13 is 
significantly higher in colorectal carcinomas of mucinous histology (Mann-
Whitney test, p = 3.74e-5). (C) Dot plot of MMP-13 gene expression and tumor 
stages. No significant difference is observed.  (D) Correlation of MMP-13 gene 
expression and Epithelial-Mesenchymal Transition (EMT) score. MMP-13 is 
significantly correlated with Mesenchymal phenotype (higher EMT score; 
Spearman correlation, Rho = 0.4468, p = 3.6e-12).  Red color line is the linear 













































Figure 47. Clinical data of MMP-13 expression level in breast cancer. (A) The 
gene expression value of MMP-13 (y-axis) is plotted for each breast cancer 
subtype, namely Basal, Claudin-low, Luminal-A, Luminal-B, ERBB2 (HER2+), 
and Normal-like.  Each dot represents MMP-13 expression level of a breast 
cancer tumor. Maroon color represents basal subtype; yellow represents 
Claudin-low subtype; light blue represents Luminal-A, whereas dark blue 
represents Luminal-B tumors. ERBB2 and normal-like tumors are represented 
by orange, and green, respectively. (B) Differential expression of MMP-13 in 
ER+ and ER- (left panel), PR+ and PR- (middle panel), and HER2+ and HER2- 
(right panel) breast carcinoma. The p-value was computed by Mann-Whitney 
test. (C) Dot plot of MMP-13 expression and tumor stages. No significant 
difference was observed. (D) Correlation of MMP-13 gene expression (x-axis) 
and Epithelial and Mesenchymal Transition (EMT) score (y-axis). No 
significant correlation is observed (Spearman correlation, Rho = -0.0012, p = 






Basal vs Rest, p = 8.3507e-06
Claudin Low vs Rest, p = 0.0599
LuA vs Rest, p = 0.2958
LuB vs Rest, p =  0.0435
ERBB2 vs Rest, p = 0.0069
Normal-like vs Rest, p = 0.0306
Rho = -0.0012
p = 0.9774




























































































Figure 48.  A complete sequence alignment of MMP-13 Hpx domain with respect to 
other MMPs using Muscle 3.6 is shown. The left panel shows the corresponding GI 
numbers of 50 homologous sequences of MMP obtained from NCBI. The box 
highlighted is the target sequence (1PEX: PDB ID) used for multiple sequence 
alignment. Conserved residues are highlighted in red colour and the HCR-13pf 
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